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ABSTRACT 
The incidence of hypervirulent epidemic Clostridium difficile has increased around the 
world and now in Australia. Assays that are capable of rapidly identifying these strains 
would enable earlier diagnosis and timely infection control response. The aims of the first 
part of the study were to validate and develop a molecular technique for the rapid diagnosis 
of toxigenic C. difficile from faecal samples using a multiplex real-time PCR assay and the 
development of a real-time PCR assay to identify strains carrying the frame shift mutation 
in the tcdC gene characteristic of hypervirulent strains. Seventy stool samples were selected 
that had been tested for C. difficile cytotoxin by cytotoxicity assay (CTA) and had C. 
difficile cultured. The DNA was extracted from C. difficile isolates and stool samples and 
tested in a conventional PCR for toxin genes. DNA extracted from stool samples was tested 
in real-time PCR. A real-time PCR targeting the tcdC frameshift mutation at position 117 
(Δ117PCR) was investigated for identifying ribotype 027 C. difficile directly from stool 
samples. Thirty-three of 70 stool samples were CTA positive and a multiplex real-time 
PCR assay agreed with 32 of these samples. Additional samples were confirmed positive by 
real-time PCR and conventional PCR of DNA from pure culture. The Δ117 PCR assay 
detected the tcdC Δ117 mutation in 1 of 70 samples and this isolate was confirmed as 
ribotype 027. Using CTA as the “gold standard”, the sensitivity and specificity for the 
multiplex real- time PCR were 97% and 51.4% respectively. Comparing conventional PCR 
results of toxin genes from isolate DNA, the sensitivity and specificity for the multiplex 
real- time PCR were 100% and 80% respectively, and comparing conventional PCR results 
of toxin genes from stool samples, the sensitivity and specificity for the multiplex real- time 
PCR were 100% and 71.4% respectively.  
 
In the second part of this study we investigated a high resolution melt analysis (HRM) of 
PCR ribotyping products. DNA was extracted from 93 clinical isolates confirmed as C. 
 
 
 
xii
difficile  through conventional tests and five control strains (ATCC 9689, R20291, CD196, 
KI and M7404 – the later four being well characterised ribotype 027 strains). Ribotyping 
was performed using the published primers of Bidet et al. (1999) and band patterns were 
analysed using GelCompar II. The same primers were used to perform real-time PCR. The 
PCR normalised melt curves were imported into ScreenClust software (QIAGEN) to 
generate principal component analysis graphs depicting clustered relationships of strains. 
Ribotyping produced clear PCR bands for 88/98 isolates tested. A dendrogram generated by 
GelCompar II showed a diversity of ribotype patterns amongst these 88 clinical isolates 
with 18 groups identified with 70% homology. Three of the four control 027 ribotype 
isolates showed 100% homology (R20291, KI and CD196). The fourth showed 82% 
homology with the other 027 control strains. One clinical isolate showed 98% homology 
with the control 027 strains and was shown to produce the toxins tcdA, tcdB, cdtA and cdtB 
and contained the frameshift mutation characteristic of epidemic 027 strains. The patient 
harbouring this strain died from complications of chronic disease and there was no evidence 
of spread of this strain to other patients. ScreenClust analysis of the same 88 HRM results 
showed clustering of isolates, with 027 strains identifiable as a unique cluster. HRM 
analysis correctly identified the control 027 stains and the clinical isolate shown also to be 
027. 
 
The real-time PCR assay of toxin genes in stool was performed in 4 hours and thus can 
serve as a rapid assay for patients suspected of having CDI. A real-time PCR targeting the 
tcdC frameshift mutation at position 117 successfully identified a ribotype 027 strain in our 
patient population. HRM analysis of the real-time PCR products of the intergenic (16S-23S 
rDNA) spacer region has enabled the identification of ribotype 027 hypervirulent strains. It 
has enabled the identification to occur within 2 – 3 hours of colony isolation and thus is a 
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valuable aid in the timely identification of these strains so that infection control can be 
rapidly implemented. 
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A review of infection and diagnosis of Clostridium difficile  
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1. Introduction  
Clostridium difficile is a well-established human pathogen causing a range of symptoms 
from mild to severe diarrhoea, and is the etiological agent of pseudomembranous colitis 
(PMC). Infection by this pathogen was found to be associated with the use of gastric acid 
suppressing agents, particularly proton pump inhibitors and antibiotics which allow 
survival of spores in the stomach and selection for C. difficile in the gut (Dial et al., 2005, 
Anand et al., 1994). However, C. difficile is not the main agent of mild antibiotic-associated 
diarrhoea in out-patients (Beaugerie et al., 2003). 
 
The first description of this organism was made by Hall and O' Toole in 1935 where the 
species name "difficile" came from the difficulty encountered during the first attempts to 
culture this organism. In addition, the organism requires at least 48 hours of uninterrupted 
anaerobic growth in order to see colonies (Hall and O'Toole, 1935). Wide distribution and 
use of antibiotics in Europe and North America after the Second World War is considered 
as the most important cause for the emergence of a new type of ‘diphtheritic-like’ PMC. 
The extensive use of some antibiotics such as clindamycin and lincomycin was clearly 
associated with this form of disease (Tedesco et al., 1974). In 1977 a previously 
uncharacterized cytopathic toxin from the stool of patients suffering from severe PMC was 
described. This toxin was suggested to be responsible in this case of inflammation, but the 
source and nature of this toxin was not pursued (Larson et al., 1977). Kuijper et al. (1987) 
reported that C. difficile was responsible for PMC as well as being responsible for some 
cases of antibiotic- associated diarrhoea (Kuijper et al., 1987). 
 
C. difficile is the most frequently identified enteric pathogen in patients with antibiotic-
associated diarrhoea and colitis (Bartlett, 1994). It accounts for 10%-25% of all cases of 
antibiotic-associated diarrhoea and virtually all cases of antibiotic-associated PMC 
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(Bartlett, 1994). Since the turn of the century the incidence of C. difficile infection has 
increased and major outbreaks in hospitals throughout many developed countries have been 
reported (Loo et al., 2005). The incidence of C. difficile infection has increased markedly in 
many countries and this increase has been suggested to be due to the emergence of a new 
hypervirulent epidemic strain known as North American PFGE type 1, REA group BI, or 
PCR ribotype 027 (Loo et al., 2005).  
 
1.1 General description of C. difficile 
C. difficile is a Gram-positive, anaerobic bacillus belonging to the family of Clostridiaceae. 
It has the ability to form subterminal endospores (Figure 1.1) in response to environmental 
stress (Voth and Ballard, 2005).  
 
 
Figure 1.1 Coloured transmission electron micrograph of C. difficile 
showing subterminal spore (Science Photos Library, www. science 
photo.com). 
 
 
This bacterium is widely distributed in soil and contaminates environments when a host 
excretes the organism in its feces (al Saif and Brazier, 1996). 
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1.2 Antibiotic-associated diarrhoea (association with human and animal disease) 
Antibiotic-associated diarrhoea (AAD) is defined as a case of diarrhoea that happens after 
administration of antibiotics with the frequency and severity of this complication differing 
depending on the type of antibacterial agent (Bartlett, 2002). Clindamycin, cephalosporins, 
broad-spectrum penicillins, and fluoroquinolones are most implicated with the problem 
though all antibiotics have been implicated (Bignardi, 1998). 
 
The incubation period before symptoms appear is variable. Symptoms can appear after one 
day of exposure to antibiotics, but it also has been reported that symptoms can arise six 
weeks after the first dose of antibiotic (Anand et al., 1994, Kelly et al., 1994). “The rates of 
diarrhoea associated with parenterally administered antibiotics, especially those with 
enterohepatic circulation, are similar to rates associated with orally administered agents” 
(Wistrom et al., 2001). Table 1-1 lists the variety of antibiotics and their risk level as a 
predisposing factor for Clostridium difficile- associated disease (CDAD) (McFarland et al., 
2000). Recently, fluoroquinolones have been reported along with cephalosporins as a major 
predisposing factor in the development of CDAD (De Andres et al., 2004). 
 
The incidence of AAD in adult hospitalised patients has been reported at 13-29%, and may 
rise to 60% during hospital outbreaks, but was less than 0.1% in out-patients (Levy et al., 
2000, McFarland, 2008). It has been proposed that the primary cause of AAD is the 
disruption of intestinal normal flora by antibiotics leading to overgrowth and colonisation 
of pathogens in the intestine. The most commonly diagnosed and potentially severe form of 
AAD is caused by C. difficile. This pathogen is implicated in 20% to 30% of patients with 
AAD, in 50% to 70% of those with antibiotic-associated colitis, and in nearly all cases of 
antibiotic-associated PMC (McFarland, 1998, McFarland et al., 1999). Besides C. difficile 
infection, other factors involved in AAD include overgrowth of other pathogens, impaired 
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faecal fermentation, and changes in dietary fibre intake (Clausen et al., 1991, Oldfield, 
2004). 
 
Table 1.1 Antibiotics associated with the development of CDAD. 
High Risk Moderate Risk Low Risk 
Clindamycin Quinolones Aminoglycosides 
Ampicillin and Amoxicillin Tetracycline Bacitracin 
Lincomycin Sulfonamides Metronidazole 
Cephalosporins (2nd and 3rd 
generation) Erythromycin Vancomycin 
 Chloramphenicol  
 Trimethoprim  
Reproduced from McFarland et al. (2000). 
 
1.3 Spread and surveillance of C. difficile 
Contaminated hands of healthcare staff and the people who come in contact with infected 
patients, in addition to environmental surfaces (e.g. floors, bedpans, toilets) contaminated 
with the bacteria or its spores play an important role in the spread of this pathogen 
throughout hospitals. This pathogen can produce spores when in unfavourable 
environmental circumstances such as being outside the body. These spores remain viable 
for a long period of time on clothes and environmental surfaces and can germinate when 
there is a return to favourable environmental conditions. 
 
In Canada and the United States outbreaks of severe C. difficile infection (CDI) have 
increased markedly since 2003 (McDonald et al., 2006, Warny et al., 2005). The emergence 
and rapid spread of a specific strain of C. difficile was the main reason for these outbreaks. 
This strain is characterized by the production of high rates of cytotoxins and enterotoxins in 
vitro and with the presence of a third toxin named binary toxin (Warny et al., 2005, Barbut 
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et al., 2005). In northern Europe (United Kingdom (UK), Belgium and the Netherlands) the 
epidemic strain began to spread in 2003 (Smith, 2005, van Steenbergen et al., 2005).  
Recently, this strain has been detected in Western Australia (Riley et al., 2009), Victoria 
(Richards et al., 2011) and Sydney (Huntington et al., 2011). 
 
A proposed surveillance system for C. difficile infections was published by McDonald et al. 
and has been adopted in Europe and the United States (McDonald et al., 2007, Cohen et al., 
2010). In 2010 the Australian Commission for Safety and Quality in Healthcare has gained 
jurisdictional agreement with Australian states to implement surveillance for CDI using an 
approach consistent with that proposed by McDonald et al. (2007) (Australian Commission 
for Safety and Quality in Healthcare, 2010). 
 
Presently, the nationwide rates of C. difficile are unknown across Australia due to 
inconsistencies in the way surveillance data is collected. Rates between 1.27 and 2.3/10,000 
bed days have been reported in some states (McGregor et al., 2005, McGregor et al., 2008). 
These reported rates are in contrast to rates of between 3.8 and 9.5/10,000 bed days 
reported in Canada in 1997 and 2005 (Cohen et al., 2010). With the appearance of the 
epidemic strain in Quebec, Canada, the rates of CDI have increased four times in Quebec 
(Pepin et al., 2005). It has been suggested that the implementation of CDI surveillance 
programs supported by international recommendations would play an important role in the 
reduction of infection rates (Cohen et al., 2010, McGregor et al., 2008).  
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1.4 Pathogenesis  
1.4.1 Initiation of disease 
C. difficile will often lie dormant as a spore waiting for an opportunity to germinate and 
begin to multiply. If a patient has received antibiotics, much of the normal bowel 
microbiota can be wiped out and hence C. difficile will germinate and grow into large 
numbers. As C. difficile grows it may produce a potent cytotoxin that can kill intestinal 
cells and also an enterotoxin that cause water to leave the remaining cells resulting in 
diarrhoea (Kelly et al., 1994). In animals C. difficile infection has been known as a cause of 
colitis (Belanger et al., 2003). In humans this organism was not known as a cause of 
diseases until 1978, when the disease was described and named as pseudomembranous 
colitis (Figure 1.2). This condition can be complicated by more serious diseases such as 
toxic megacolon, perforation and peritonitis (Poxton et al., 2001).  
 
 
Figure 1.2 PMC, post-mortem specimen. Note the areas of intense inflammation 
(Poxton et al., 2001). 
 
The mode of disease transmission of C. difficile is through the faecal oral route. Ouwehand 
et al. (2002) have stated the digestion and absorption of food and the generation 
of antibodies is the key role of intestinal microflora (Ouwehand et al., 2002). The size of 
the pathogen population is controlled by being prevented from overgrowth by the 
 8  
microflora which form part of the intestinal mucosal barrier; this barrier is regulated by the 
immune system (Poutanen and Simor, 2004, Wilson, 1993).  
 
The mechanism of C. difficile infection and pathogenesis was first demonstrated by the use 
of a hamster model (Wilson, 1993). When vegetative cells and spores of C. difficile are 
ingested, most of the vegetative cells are killed by stomach acid and only about 1% reaches 
the small intestine. These vegetative cells are inhibited by intestinal microflora and are 
removed from the body in the stool. Spores however can survive in the stomach, pass 
through to the small intestine and the action of bile salts induces spore germination. In the 
absence of microflora these germinated cells can colonise the colon and toxigenic strains 
will produce two large toxins named toxin A and toxin B. "Both toxins disrupt the actin 
cytoskeleton of intestinal epithelial cells by uridine diphosphate-glucose dependent 
glycosylation of Rho and Ras proteins" (Rupnik et al., 2005). It has also been suggested 
that these toxins bind to the receptors on epithelial cells resulting in an inflammation 
followed by diarrhoea. These toxins then lead to breakdown of the junction between 
epithelial cells which is then followed by perforation and penetration in the intestine (Starr, 
2005). It has been reported that toxins A and B stimulate the release of tumor necrosis 
factor-alpha and proinflammatory interleukin, which produces pseudomembrane formation 
and the inflammatory process (Poxton et al., 2001).  
 
1.4.2 C. difficile toxins (A and B) 
It was noted that a culture filtrate of this organism could kill inoculated rabbits, even 
though the organism was first isolated from healthy infants (Hall and O'Toole, 1935). When 
CDI was first investigated, the two toxins were described independently and initially 
confused (Larson et al., 1977). 
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A large toxin was found when ion exchange chromatography was used to separate secreted 
proteins as reported by two independent research groups in 1981, that toxin was named as 
toxin A (Taylor et al., 1981, Banno et al., 1984), toxin A was able to produce fluid 
accumulation in ligated ileal loops of rabbits while toxin B could not; in addition, toxin A 
produced less rounding of fibroblasts in culture. “Toxin A produced a similar profile as 
total supernatant, when given intragastrically, which toxin B did not, unless mixed with 
small amounts of toxin A, or given to animals with bruised ceca” (Lyerly et al., 1985). 
 
We now know that disease-causing C. difficile produce at least two toxins (Lyerly et al., 
1988). Experiments on laboratory animals showed that toxin A has a cytopathic effect on 
cells while toxin B caused epithelial cell rounding and death and is up to a thousand-fold 
more toxic in laboratory cell culture assays (Voth and Ballard, 2005). Toxin A was thus 
thought to be the principal virulence factor while toxin B required toxin A to be present and 
begin the cascade of break to the colonic mucosa and create disease (Lyerly et al., 1988). 
 
Before the development of genetic tools to manipulate C. difficile, natural mutations and 
variations in the toxin genes of C. difficile were sought out to shed some light on their 
function and role in pathogenesis, especially in the debate as to which toxin was most 
important. Some of C. difficile strains were clinically reported to cause disease when they 
produced no detectable toxin A. This challenged the current thinking, and was not only 
academically interesting, but it also had ramifications for clinical practice. At that time, 
clinical immunoassays only tested for the presence of toxin A.  
 
Sequencing of the reference strain VPI 10463 has revealed that there are five genes within a 
19.6 kb pathogenicity locus (PaLoc) known as  tcdA, -B, -C, -E and -R (Figure 1.3) 
(Hammond and Johnson, 1995).  The two major toxins encoded by the pathogenicity locus 
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are toxin A (primarily an enterotoxin) and toxin B (a cytotoxin). Strains that are non-
toxigenic have a 115-bp DNA fragment bordered by two insertion sequences which has 
replaced PaLoc (Braun et al., 1996, Cohen et al., 2000, Hammond et al., 1997). 
 
Strains reported to be toxin A negative and toxin B positive have been isolated from 
patients with CDAD and colitis (Savidge et al., 2003). Strain 8864 was the first toxin A-
negative toxin B positive (A-/B+) described (Lyerly et al., 1992), producing no toxin A in 
vitro by immunoassay, and a toxin B found to be more lethal and weakly enterotoxic to 
animals. Sequencing of the TcdA gene and TcdC gene of strain 8864 was later shown to 
have deletions at the 3’ends of these genes. This truncation in the resulting toxin A protein 
lacks the receptor binding repeats and translocation domain (Soehn et al., 1998). While 
isolates like strain 8864 remain rare, other disease-causing A-B+ strains have been reported 
more frequently in the early 1990’s. Strain 1470 and related isolates (Depitre et al., 1993, 
Sambol et al., 2000), also have deletions in tcdA and are negative in clinical tests for toxin 
A. They were initially thought to be non-pathogenic in mice (Depitre et al., 1993), but 
further work in the more sensitive hamster model (Sambol et al., 2001) and fatal cases in 
humans (Johnson et al., 2001) and human epidemics soon dismissed this idea (Alfa et al., 
2000, Kuijper et al., 2001). Toxin B from these strains was found to share homology with a 
toxin from a related Clostridium species, TcsL from C. sordelii (Chaves-Olarte et al., 
1999), in its enzymatic domain, which allows it a larger range of host molecule specificity 
and increased toxicity. This variation in Toxin B’s enzymatic domain left the debate 
concerning toxin A versus B open. 
 
Stabler et al. (2008) have reported the results of assays that showed the toxin B has more 
binding capacity than toxin A. Both toxin A and B have a cytotoxic effect on many 
different cell types. Others have reported that the effect of toxin B is greater than the effect 
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of toxin A and both lead to increased vascular permeability due to breakdown of the 
junction between epithelial cells that can result in haemorrhage (Borriello, 1998, Poxton et 
al., 2001). 
 
Recent advances in the genetic manipulation of C. difficile have provided a molecular 
scientific answer to the question of which toxin is most important to disease. Using an 
unstable plasmid as a recombination vector produced isogenic mutants of tcdA and tcdB in 
strain 630 (Lyras et al., 2009, O'Connor et al., 2006). When these mutant strains were 
introduced into the hamster model, it was shown that toxin B was the required virulence 
factor. Hamsters infected with the toxin A mutants showed no difference in mortality as 
compared to the wild-type. In contrast, the group of hamsters infected with the toxin B 
mutant C. difficile showed significantly less mortality, and analysis of the C. difficile 
obtained from the fatal cases indicated that they were revertant strains in which the 
recombination vector was excised: this supported the idea that toxin B production is 
favoured for pathogenesis and survival in the gut (Lyras et al., 2009). 
 
However, a more recent study has reported conflicting results. Using the ClosTron system 
of a re-targetable group II intron (Heap et al., 2007), null mutations were made in tcdA and 
tcdB (Kuehne et al., 2010). In contrast to the previous study, both toxins contributed to 
virulence in the hamster model. However, hamsters infected with C. difficile lacking toxin 
B survived for several days longer than those infected with C. difficile lacking toxin A 
(Kuehne et al., 2010). While both may participate in the disease process, it appears that 
toxin B makes the larger contribution to virulence. 
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1.4.3 Binary toxin (cdtA and cdtB) 
Several gram-positive spore-forming species produce another type of toxin called binary 
toxin. This toxin has been particularly well characterized among Clostridium and Bacillus 
spp. (Barth et al., 2004) and is produced in a minority of strains from patients diagnosed 
with PMC and is considered as one of the characteristics of the current hypervirulent strain 
(Cloud and Kelly, 2007). 
 
Binary toxin is not found in historical strains, but is produced by strains isolated from pigs 
and calves (Keel et al., 2007). Binary toxin is composed of two unlinked components, the 
enzymatic and the binding components which act as an actin specific ADP 
ribosyltransferase (Perelle et al., 1997). Barbut et al. (2005) reported that the binary toxin 
genes (cdtA) and (cdtB) together encode this toxin and induce the production of an actin 
specific ADP- ribosyltransferase which leads to a breakdown of the actin skeleton, followed 
by cytopathic effects in cell lines (Barbut et al., 2005). 
 
1.4.4 Putative negative regulator (TcdC) 
The TcdC gene is considered as a negative regulator gene for both toxins A and B 
(Spigaglia and Mastrantonio, 2002). The hypervirulent strain recently involved in epidemic 
(PCR ribotype 027 in Europe and North American (NA) pulsed-field type 1 (NAP1/ BI) in 
the USA) is said to cause more severe disease and lead to higher rates of morbidity and 
mortality than other strains of C. difficile (Kuijper et al., 2006). The severity of the 
hypervirulent strain is thought to be due to the production of high levels of TcdA and TcdB 
toxins caused by two deletions detected in this tcdC gene (Warny et al., 2005). 
 
Sequencing of ribotype 027 strains revealed an 18 bp deletion in the TcdC toxin repressor 
gene, in addition to a highly-conserved point deletion at position 117 (Δ117) in tcdC that 
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introduces a frameshift mutation truncating the predicted TcdC product to 65 amino acid 
residues (MacCannell et al., 2006). Thus the presence of Δ117 mutation in the TcdC gene 
can be used as a marker for the detection of the 027/NAP1/ BI epidemic strain (MacCannell 
et al., 2006). In recent years many studies using real-time PCR assays targeting the Δ117 
mutation in tcdC for detection of the epidemic strain have been conducted including 
melting curve analysis (Sloan et al., 2008, Wolff et al., 2009).     
 
Figure 1.3 Pathogenicity locus of C. difficile and the domain distribution of TcdA, TcdB 
and TcdC genes. 
 
1.5 Laboratory diagnosis of C. difficile  
1.5.1 Culture 
In order to identify disease producing strains of C. difficile, laboratories use different types 
of techniques including culture, cytotoxicity assay (CTA), or enzyme immunoassays (EIA) 
for the detection of toxigenic C. difficile in faecal samples (Turgeon et al., 2003). Detection 
of toxigenic C. difficile by isolation of pure culture is the most sensitive laboratory test in 
clinical use, but it is not as specific as the cell cytotoxicity assay and is time consuming 
(Gerding et al., 1995). Weese et al. (1999) reported that the lack of specificity in 
determining toxin producing strains may result in the reporting of toxin-negative strains and 
the delay in sample processing may lead to a reduction in the survival rate of organisms in 
stool samples resulting in false negative culture results (Weese et al., 1999). 
 
There is still much debate about patients who were diagnosed with CDAD and have a 
negative stool toxin test, but have C. difficile recovered from their stool specimens by 
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culture. Because nontoxigenic strains are not considered pathogenic, the determination of in 
vitro toxin production by isolates cultured from toxin negative stools may help somewhat to 
resolve this dilemma (Shanholtzer et al., 1992). 
 
1.5.2 Toxin detection 
Toxin B in stool can be used as a marker for the presence of toxigenic bacteria in a stool 
sample (Gerding et al., 1995). The cytotoxicity assay was considered as the gold standard 
for detection of C. difficile toxin B in stool, where the sensitivity can be ≤ 85 % (Bouza et 
al., 2001). This percentage rises to ≤ 99% when the cytotoxicity assay is combined with 
toxigenic culture (i.e., C. difficile broth culture followed by CTA performed on the culture 
broth); however this improvement in sensitivity is associated with an increased cost of 
detection (Bouza et al., 2001, Peterson et al., 1996). In addition, the final reading of this test 
can take up to 4 days of incubation and requires tissue culture facilities (Peterson et al., 
1996). 
 
Many researches state that the detection of C. difficile by toxigenic culture is more sensitive 
than the cytotoxicity assay, even though the specificity is still under review (Bartlett and 
Gerding, 2008). 
 
Enzyme immunoassays (EIA) based on monoclonal antibodies against toxin A and/or B 
have been commonly used for toxin detection, although these EIAs are not as sensitive as 
the cytotoxicity assay and the specificity of such assays have been questioned (Barbut et al., 
1993, Shanholtzer et al., 1992). 
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1.5.3 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is used for the detection of toxin genes of C. difficile. 
PCR methods are more rapid and  have higher sensitivity and specificity when compared to 
culture-based methods (Louie et al., 2000). False positive PCR results obtained by 
amplification of nonspecific products have been decreased by the use of fluorescent 
labelled probes in real-time PCR assays (Houser et al., 2010). This is because binding of 
the probe as well as the primers to the target sequence is needed for a signal to be produced. 
The accuracy of PCR detection methods has become more reliable due to the specificity of 
primers and probes to DNA targets (Louie et al., 2000). 
 
A traditional PCR assay targeting the tcdB gene only has been developed where the 
specificity and sensitivity were 100% and 91.5% respectively (Guilbault et al., 2002). Van 
den Berg et al. reported similar results when cytotoxicity assay results were compared to 
the results of a real-time PCR assay targeting the tcdB gene. The sensitivity, specificity, 
positive predictive value, and negative predictive value were 100%, 97%, 55%, and 100%, 
respectively when a cytotoxicity assay was used as gold standard (van den Berg et al., 
2006). In a study presented in 2007, it was reported that culture concordance values of 
VIDAS immunoassay, the PTAB immunoassay, and a real-time PCR assay were 53.6%, 
55.4%, and 71.4%, respectively when compared with the cell cytotoxicity assay (van den 
Berg et al., 2007). The sensitivity, specificity, positive predictive value and negative 
predictive value of PCR assay targeting tcdB was 93.3%, 97.4%, 75.7%, and 99.4%, 
respectively when compared with enzyme immunoassay (Peterson et al., 2007). A 
comparison of a commercial real-time PCR assay for tcdB detection and cell cytotoxicity 
assay to toxigenic culture which is considered as the gold standard showed a sensitivity, 
specificity, positive predictive values, and negative predictive values of 83.6%, 98.2%, 
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89.5%, and 97.1% and 67.2%, 99.1%, 93.2%, and 94.4 %, for real-time PCR assay and cell 
cytotoxicity assay, respectively (Stamper et al., 2009a). 
In a comparison study between nine commercially available C. difficile toxin detection 
assays, Eastwood et al. reported that the real-time PCR assay had the highest sensitivity and 
highest negative predictive value than all other detection assays (Eastwood et al., 2009). 
Kvach et al. (2010) also reported that a real-time PCR assay was more sensitive (p=0.0001) 
than a C. difficile toxin immunoassay. A multiplex assay targeting toxin genes tcdA and 
tcdB as well as tpi a housekeeping gene specific to C. difficile was developed by Lemee et 
al. (2004). It allows combined diagnosis and toxigenic type characterization for human and 
animal C. difficile intestinal infections (Lemee et al., 2004). 
 
The emergence of new toxigenic C. difficile strains such as TcdA negative/TcdB positive 
strains as well as TcdA negative/TcdB negative/CDT positive strains make tests based on 
the detection of a single toxin unreliable (Geric et al., 2003, Drudy et al., 2007). Persson et 
al. (2008) developed a molecular method for the detection of pathogenic C. difficile 
isolates, including a multiplex PCR for detecting the genes encoding TcdA, TcdB and 
binary toxin; and a sequencing-based method for investigating deletions and premature stop 
codons in tcdC gene. 
 
Recently researchers have reported some TcdA negative/TcdB negative strains shown to 
produce both cdtA and cdtB, suggesting binary toxin may be considered as a virulence 
factor since the binary toxin protein has the ability to increase the adherence ability of C. 
difficile to the intestinal wall (Schwan et al., 2009). In a study conducted by Geric et al. 
(2003) that reported the frequency of binary toxin genes (cdtB and cdtA) among C. difficile 
isolates that do not produce toxin A and B, it was found that 15.5% of tcdA and tcdB 
negative C. difficile isolates examined were positive for both cdtA and cdtB. Therefore, 
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assays that detect toxigenic C. difficile based on the presence of only tcdA and tcdB may 
miss isolates only carrying binary toxin. Until more is known about the significance of 
these isolates there is a need for a reliable, high throughput, multiplex real-time PCR assay 
capable of detecting genes encoding for all three toxins. 
 
1.6 Typing of C. difficile 
Typing of C. difficile can lead to a greater understanding of the strain causing disease in 
humans and the epidemiology of C. difficile. By typing different strains, we can track the 
spread of new strains throughout healthcare facilities and geographical areas and determine 
when outbreaks are occurring in a region. Although there are a variety of typing methods 
available for bacteria, not all typing methods are equally valuable for each species. Optimal 
typing methods also depend on the specific objectives and different typing methods may be 
better for different applications. In general, the main characteristic of a valuable typing 
methodology are discriminatory power, reproducibility, ability to standardise protocols and 
technical aspects such as ease and cost. By having a highly discriminatory typing method, 
strains that appear to be identical using one method can be differentiated using a different 
typing method. A highly discriminatory typing method is particularly useful when 
investigating local outbreaks. Reproducibility involves the ability to obtain the same results 
when the method is used at different times and by different laboratories. This is important 
for any comparisons that take place over time or where comparisons with external 
laboratories are needed. 
 
There are many different typing methods proven to be effective in the typing of C. difficile. 
Some of these methods depend on phenotype such as lysotyping and others on genotype 
such as restriction endonuclease analysis (REA) of the total bacterial genome (Kuijper et 
al., 1987, Kato et al., 1993), pulsed-field gel electrophoresis (PFGE) of enzyme-restricted 
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whole genome DNA, arbitrarily primed PCR (AP-PCR) (Killgore and Kato, 1994, Fawley 
and Wilcox, 2002, Rodriguez-Palacios et al., 2007), and PCR-ribotyping (Gurtler, 1993). 
Genotypic methods are based on the analysis of the genetic profile of the organism, 
whereas the analysis of gene expression is the main basis of phenotypic methods. Before 
plasmid and whole-genome restriction analysis become available as typing methods in the 
1980’s, serotyping was the most used phenotypic technique (Clabots et al., 1988, Kuijper et 
al., 2009). Due to the ease and rapidity of analysing DNA, whether amplified or not, 
genetic methods tend to be the most common methods used in recent years. 
 
1.6.1 Pulsed-field gel electrophoresis (PFGE) 
Pulsed-field gel electrophoresis is an example of a typing method that depends on a whole-
genome restriction analysis. After embedding cells in agarose the total genomic DNA is 
extracted using proteinase K and mild detergent. DNA fragments are produced after the 
whole genome is digested by restriction enzymes, these fragments are separated in a gel 
depending on its molecular weight in a specialized electrophoresis unit with a pulsing 
electrical field (Schwartz and Cantor, 1984). 
 
Grouping and classification of isolates occur based on the bands produced by this method. 
PFGE was first applied to characterise C. difficile isolates by Kato and colleagues in 1994 
(Kato et al., 1994). PFGE is considered the gold standard and characterized by very high 
discriminatory power for molecular typing of C. difficile (Kato et al., 1994). However, this 
method is not practical in an outbreak situation due to the length of the protocol as from 4 
to 6 days is required to obtain typing results using this method. In addition, manual labour 
requirements, expensive equipment requirements, and hazardous chemicals used by this 
method have resulted in a decrease in the use of PFGE as a main typing method (Gal et al., 
2005). 
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1.6.2 Restriction endonuclease analysis  
REA is another method using genomic-level comparison of restriction fragment length 
polymorphisms (RFLP) to differentiate between bacterial species or strains. It differs from 
PFGE, where rare cutting endonucleases are selected, and fragment sizes often range into 
the hundreds of kilobases while PFGE is able to resolve extremely large nucleic fragments. 
REA uses digestion of the whole genomic DNA by restriction enzymes resulting in 
fragments that are separated by electrophoresis (Clabots et al., 1993). The technique has a 
high discriminatory power, however it is technically demanding, the interpretation is 
subjective and data exchange between laboratories is difficult (Kuijper et al., 2009). 
 
1.6.3 PCR-ribotyping     
PCR-ribotyping has been reported to provide a discriminatory, reproducible, and a simple 
alternative to other typing methods (Cartwright et al., 1995). PCR-ribotyping was first 
described by Kostman et al. in 1992 in a study of the epidemiology of  Burkholderia 
cepacia, where it was proposed as an alternative to the more classical ribotyping methods 
(Kostman et al., 1992). Unlike traditional ribotyping, which analyses strain-specific 
differences in the coding sequences of the 16S and/or 23S ribosomal genes, PCR-
ribotyping amplifies the intergenic spacer region (ISR) between the two, using primers 
from the highly-conserved 16S and 23S termini. 
 
Gurtler in 1993 described the first PCR-ribotyping for C. difficile and demonstrated that C. 
difficile isolates may contain up to 16 different alleles of the rRNA operon, with varying 
intergenic topologies (Gurtler, 1993). The PCR-ribotyping technique has a number of 
advantages over other methods specifically PCR-ribotyping has been shown to be more 
discriminatory than arbitrary-primed PCR (AP-PCR) (Collier et al., 1996), and is quicker 
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and simpler than PFGE. PCR-ribotyping also avoids the excessive endogenous nuclease 
activity of some C. difficile isolates that renders them untypeable by PFGE (Stubbs et al., 
1999). Furthermore, the PCR-ribotyping technique is "considered to be highly 
discriminative, reproducible and can be performed relatively easily and rapidly" (Arroyo et 
al., 2005). Because of this, PCR-ribotyping is more amenable to rapid and high-volume 
strain typing, or epidemiologic projects where only limited amounts of the genomic 
template are available for study (MacCannell et al., 2006). 
 
1.7 The emergence of a hypervirulent strain 
From 2003 evidence emerged that C. difficile was becoming more virulent and the disease 
more complicated and more resistant to standard treatment. In the USA, Canada and Europe 
one strain of C. difficile associated with this severe disease was reported as ribotype 027 in 
Europe and NAP1/ BI in the USA (Cookson, 2007). The first report of PCR ribotype 027 
was in 1988 from the culture collection of M. Popoff  (Paris, France). This isolate was from 
a 28-year-old woman suffering from severe PMC (Kuijper et al., 2006). 
 
Warny et al. (2005) have reviewed the emergence of ribotype 027 in the hospitals of 
Montreal and Southern Quebec, Canada and noted the increased incidence of infection. 
They also reported that the rates of CDI had been elevated between 2003 and 2004 and 
reached 14,000 nosocomial cases with an incidence of more than 15 per 10,000 in-patients 
in January 2005. This was reported to be five times greater than the historical average 
(Warny et al., 2005). 
 
In the UK two outbreaks of CDI occurred with one outbreak reaching a mortality of 
approximately 11% in the period between 2003 and 2005 at the Stoke-Mandeville Hospital. 
These outbreaks were characterised by an increase in mortality and resulted in the deaths of 
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38 patients in total for both outbreaks (Buckinghamshire Hospitals, 2006). It has been 
proposed that the increased severity of this hypervirulent strain is related to high production 
of toxins A and B caused by two deletions in the TcdC toxin regulator gene (Spigaglia and 
Mastrantonio, 2002).In the USA there have been more than 250,000 cases of CDAD 
diagnosed per year, which costs the health care system over $1 billion (Wilkins and Lyerly, 
2003).  
 
Before the emergence of this epidemic ribotype 027 strain, data describing the incidence 
and prevalence of the various ribotypes of C. difficile in Australia had not been reported. 
The incidence of C. difficile in Western Australia hospitals during the 1980s was high but it 
declined “from 2.09 cases per 1,000 discharges in 1998 to 0.87 cases per 1,000 discharges 
in 1999” and was assumed to correlate with a decreased use of broad-spectrum 
cephalosporins  (Thomas et al., 2002). 
 
The first reported isolation of ribotype 027 in Australia occurred at the end of October 2008 
in Western Australia when a 43-year-old woman presented with diarrhoea and a permanent 
ileostomy. She was believed to be infected while travelling in the United States (Riley et 
al., 2009). This isolate was positive for tcdA and tcdB as well as both cdtA and cdtB binary 
toxin genes and showed resistance to many antibiotics especially fluoroquinolones. In 
addition, the sequencing of the TcdC gene (putative negative regulator) indicated that the 
strain contained an 18 bp deletion as well as a one bp deletion at position 117 which is the 
characteristic feature of the ribotype 027 epidemic strain (Riley et al., 2009). 
 
An epidemic hypervirulent 027 ribotype strain was also recognised in a hospital in 
Melbourne, Australia in late January 2010 (Richards et al., 2011), when an 83-year-old 
Latvian man was admitted to hospital. This patient had undergone an aortic valve 
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replacement for aortic stenosis. After five days of surgery the patient developed watery 
diarrhoea and C. difficile was isolated from a stool sample. This isolate was considered to 
be the first report of a ribotype 027 acquired in Australia (Richards et al., 2011). It is likely 
that the 027 strain is now well established in Australia as shown by the number of isolates 
reported by Huntington et al. (2011). 
 
It has been reported that the levels of toxins A and B produced by the new epidemic strain 
PCR ribotype 027 are 16 to 23 times higher than toxin A and toxin B produced by non-027 
toxigenic strains (Warny et al., 2005). In another study, it was reported that the risk of 
developing severe CDAD caused by this hypervirulent strain is twice that of the CDAD 
caused by a non- PCR ribotype 027 strains (Hubert et al., 2007). However, Carter et al., 
(2011) found that tcdC-status is not correlated with toxin production in clinical isolates.  
Hence, these authors have raised a question about the accuracy of assigning gene function 
by studying non-isogenic strains, particularly in a highly heterogeneous species such as C. 
difficile. 
  
National surveillance programs do not cover the entirety of the European continent and an 
estimation of the incidence of ribotype 027 incidence is not easy. Nine of a total of 16 
European countries have reported outbreaks due to ribotype 027 epidemic strain (UK, 
Netherlands, Belgium, France, Ireland, Luxembourg, Switzerland, Germany and Finland) 
while the remaining 7 countries (Austria, Denmark, Sweden, Norway, Hungary, Poland and 
Spain) have reported random cases in 2008 (Kuijper et al., 2008). 
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1.8 Control of C. difficile disease 
The basic strategy used to treat patients with CDAD is stopping the intake of any other 
antibiotics if possible. One of the recent studies found that 41% of patients failed 
treatment with metronidazole when other antibiotics were not stopped (Gould and 
McDonald, 2008). Metronidazole and vancomycin are considered the primary agents 
used to treat CDAD. Metronidazole treatment is preferred because it is less expensive 
and less likely to promote the selection of vancomycin-resistant Enterococcus spp. 
(Gould and McDonald, 2008). Gold and McDonald also report that some recent 
treatment failure of metronidazole has been reported especially in patients with severe 
complications. Metronidazole and vancomycin should be administrated orally if possible 
and anti-peristaltic agents should be avoided. Early surgical operations sometimes 
improve the survival of patients with fulminate disease (Gould and McDonald, 2008). 
 
The emergence of the hypervirulent strain has increased interest in C. difficile typing and 
stimulated the application of newer genotype-based methods. Faster typing techniques 
will enable the quicker detection of hypervirulent strains and the timely implantation of 
infection control strategies. 
 
Improvement in the prevention and control of CDI armed by surveillance should be 
integrated into quality improvement efforts. Screening tests must be mandatory for all 
patients who develop diarrhoea after 48 hours of admission to a hospital. A stool test 
positive for toxigenic C. difficile or its toxins or colonoscopic and/or histological findings 
of PMC with the presence of symptoms (usually diarrhoea) are important points for case 
definition (Cohen et al., 2010). 
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In order to implement effective infection control precautions, infection control 
professionals and clinicians must be informed in a timely fashion when CDI cases have 
been detected (Cohen et al., 2010).  Due to the possibility of CDI presenting in patients 
from residential aged care facilities or from the community, hospitals should also be 
alerted of the patient’s history which may indicate a predisposition to CDI. Follow-up of 
patients who have one or more risk factors leading to CDI such as antibiotics exposure, 
old age or who have long hospital stays  and testing of outpatients > 60 years of age who 
are suffering from diarrhoea should be taken into account (Australian Commission for 
Safety and Quality in Healthcare, 2010). 
 
Hand hygiene plays an important role in the prevention of healthcare associated infection 
(HAI). A combination of educational programs and alcohol-­‐based hand disinfection has 
revolutionised the practice of point of care hand hygiene. Reductions in HAI with 
methicillin-­‐resistant Staphylococcus aureus  (MRSA) have been reported to be related to 
an increase in the compliance to a hand hygiene program (Grayson et al., 2008, McLaws 
et al., 2009). Prevention of the transmission of C. difficile is also facilitated by hand 
hygiene (Gerding et al., 2008), but the best method of control is unknown. Several recent 
studies have shown that the extensive use of alcohol hand hygiene actually increases the 
spread of CDI (Boyce et al., 2006, Gordin et al., 2005). This is because C. difficile spores 
are resistant to alcohol hand hygiene products and soap and water is the preferred hand 
hygiene method (Boyce et al., 2006). 
 
A main role of a surveillance programme is to identify new emerging strains of C. 
difficile. CDI caused by certain strain types, in particular ribotype 027, has been 
associated with a more severe course of disease, higher mortality and increased 
transmissibility between persons. Early detection of new emerging hypervirulent strains 
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is essential to control and prevent the spread of such clones. In new surveillance 
programmes, laboratories should culture for C. difficile from cases of severe CDI 
(including cases of PMC) and from cases in suspected outbreaks. The cultured isolates 
could then be characterised by ribotyping in a central reference laboratory. The culture 
and typing of C. difficile would be useful in investigating whether there are links between 
individual cases and in monitoring the spread of infection from particular strains of C. 
difficile. 
 
1.9 Objectives and specific aims 
This study aims to trial a molecular technique for the rapid diagnosis of toxigenic C. 
difficile directly from stool samples. Secondly, we also aim to investigate a real-time PCR 
assay to identify those strains carrying the frameshift mutation (Δ117 mutation) in the tcdC 
characteristic of hypervirulent strains. Thirdly we aim to develop a new method to track 
highly lethal hospital-acquired infections due to C. difficile based on the melt curve analysis 
of PCR products obtained from the ISR of C. difficile. 
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CHAPTER 2 
Development of a Multiplex Real-Time PCR for the Detection of Toxigenic 
Clostridium difficile and Subsequent Identification of the tcdC Δ117 Mutation in 
Human Faecal Samples 
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2.1 Introduction 
Laboratory diagnosis of C. difficile should include testing of stool samples by isolation of 
C. difficile on culture or cytotoxicity testing as EIA methods for detection of toxins are 
insufficiently sensitive. PCR amplification of target genes is known to have very high 
specificity and sensitivity when compared to other pathogen detection methods (Louie et 
al., 2000). The advent of probe based real-time PCR has further increased the specificity 
and sensitivity of such assays. Probe based real-time PCR assays allow detection of targets 
much earlier during PCR cycling and negates the need for post-assay analysis of the PCR 
product. Therefore, probe based real-time PCR allows the acquisition of results in less time 
as compared to other diagnostic methods. 
 
Persson et al. (2008) reported on a multiplex PCR assay for detection of C. difficile toxin 
genes and found that their PCR method was useful to characterise strains for the important 
toxin genes. Wroblewski et al. (2009) used a real-time PCR assay to detect the same genes 
and found they could also detect these genes directly from stool samples (Wroblewski et 
al., 2009). Recently de Boer et al. (2010) published a real-time PCR method that could 
discriminate between wild-type tcdC and the mutant form characteristic of ribotype 027. In 
order to perform PCR testing, it is important to select a DNA extraction method that will 
give reliable results. 
 
DNA extraction from pure cultures and stool samples using commercial kits is relatively 
time consuming, labour intensive and introduces the possibility of contamination. The 
robotic QIAsymphony SP can be used to avoid the issues associated with manual kits. 
Moreover, a robotic pipette can be used for aliquoting PCR master mix and DNA and thus 
decrease the pipetting errors that may occur with manual pipetting. 
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The research questions we aimed to answer in this part of the study were 
1. Can published primers and probes for C. difficile toxin genes be improved by 
considering alignments with the latest published sequences? 
2. Does real-time PCR perform as well as conventional PCR for stool DNA? 
3. Does a deletion assay for the TcdC gene give similar results when used in the Rotor-
Gene platform? 
4. Does the use of a real-time multiplex assay for C. difficile toxin genes lead to reliable 
results?  
5. Can an automated system  (QIAsymphony SP and a robotic pipette) be used to reliably 
detect C. difficile toxin genes and the Δ117 mutation? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29  
2.2 Materials and Methods 
An overall flowchart for the testing is provided in Figure 2.1. Details are provided in the 
following sections. 
 
 
 
Figure 2.1 Flowchart of sample testing 
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2.2.1 Clinical specimens and bacterial isolates 
Stool samples (70) with positive results for C. difficile isolation were collected from the 
Microbiology Department at Austin Health (Melbourne, Australia) during the period 
between May 2009 and May 2010. Approximately 1 ml of each sample was frozen at -
80°C. These stool samples had also been previously tested for C. difficile cytotoxin in cell 
culture cytotoxicity. C. difficile was re-isolated from samples by culturing the frozen stool 
specimens onto C. difficile selective media (Cycloserine Cefoxitin Blood Agar) and the 
plates were incubated for 48 h at 37°C in an anaerobic chamber. A colony showing typical 
C. difficile morphology was then sub-cultured onto the same media and incubated as 
previously stated. The isolates were confirmed as C. difficile through colonial morphology 
and characteristic odour, Gram stain and CD Agglutination Test (OXOID, Adelaide, 
Australia) performed according to the manufacturer’s instructions. A further 23 isolates 
were forwarded from Austin Health directly after isolation from faecal samples. 32 of the 
70 stool samples were reported to be positive in the cytotoxicity assay performed by Austin 
Health. Five references strains were included as controls: C. difficile ATCC9689 and four 
C. difficile PCR ribotype 027. The control strains were: CD196, the original non-epidemic 
strain first isolated in Paris in 1985 (Popoff et al., 1988); R20291, a representative strain 
from the 2006 Stoke Mandeville outbreak in the United Kingdom (Stabler et al., 2009); 
M7404 provided by J. Pepin to Monash University, Australia (Carter et al., 2007) and a 
representative of the Canadian outbreak in 2005 (Loo et al., 2005); and KI, a strain locally 
acquired in Melbourne, Australia causing severe infection (Richards et al., 2011). These 
strains were kindly supplied by Dena Lyras and Glen Carter, Department of Microbiology, 
Monash University.  
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2.2.2 Extraction of DNA from bacterial isolates                
DNA was extracted from isolated C. difficile colonies using a Wizard® Genomic DNA 
Purification Kit (Promega, San Diego, USA). Briefly, ten colonies were resuspended 
thoroughly in 480 µl of 50 mM EDTA.  60 µl of 20 mg/ml lysozyme was added to the cell 
pellet to weaken the cell wall. The cell suspensions were incubated at 37°C for 45 minute 
(min) and then centrifuged at 13,000 x g for 3 min. The supernatant was then removed and 
600 µl of Nuclei Lysis Solution was added and then samples incubated at 80°C for 5 min 
then cooled to room temperature. 200 µl of Protein Precipitation Solution was then added to 
the solution and vortexed vigorously for 20 sec. Samples were then incubated on ice for 5 
min and centrifuged at 13,000 x g for 4 min. The supernatant containing the DNA was then 
transferred to a clean 1.5 ml microcentrifuge tube containing 600 µl of room temperature 
isopropanol. The samples were then mixed gently until thread-like strands of DNA formed 
a visible mass and then the samples were centrifuged at 13,000 x g for 3 min. The 
supernatant was carefully poured off and the tube was drained on clean absorbent paper. 
600 µl of room temperature 70% ethanol was then added and the tube gently inverted 
around ten times to wash the DNA pellet. The samples were centrifuged at 13,000 x g for 3 
min and the ethanol carefully aspirated. The tubes were then drained on clean absorbent 
paper and the pellet allowed to air dry for 15 min. 100 µl of DNA Rehydration Solution 
was added to the tubes and the DNA rehydrated by incubating at 65°C for 1 h with the 
solution mixed periodically. The DNA solution was then cooled to room temperature and 
stored at 4°C. 
 
2.2.3 Extraction of DNA directly from stool samples 
Stool samples were centrifuged at 13,000 x g for 4 min and the supernatant was removed in 
order to leave 500 µl including the sediment. The sediment was then re-suspended in the 
500 µl and the total was divided into two parts (each 250 µl). DNA was extracted using 
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QIAamp® DNA Stool Mini Kit (QIAGEN, Hilden, Germany) on 250 µl of the faecal 
suspension and QIAsymphony SP automated systems (QIAGEN) on the remaining 250 µl 
of the faecal suspension. The QIAamp® DNA Stool Mini Kit was used according to the 
manufacturer's instructions. Briefly, stool samples were homogenized in 1.5 ml of buffer 
ASL and heated at 95°C for 5 min to lyse bacterial cells. After removal of potential 
inhibitors by incubation with an InhibitEx tablet (QIAGEN) the lysates were treated with 
15 µl proteinase K and 200 µl buffer AL at 70°C for 10 min to remove protein 
and polysaccharides. DNA was precipitated by adding 200 µl of ethanol (97%) to the lysate 
and then applied to a column provided in the kit. This was followed by washes with 500 µl 
of buffers AW1 and AW2 and centrifuged at full speed for 3 min. The QIAamp spin 
column containing the filtrate was discarded and sediments dissolved in 200 µl buffer AE.  
For the DNA extracted by The QIAsymphony, the stool samples were prepared as 
described above. 250 µl of each sample was loaded into the machine and DNA extraction 
was performed using the QIAsymphony Virus/Bacteria Mini Kit (QIAGEN) using the 
QIAsymphony “Complex200 V3 default IC” extraction protocol which extracted DNA 
from 200 µl of the 250 µl presented. The resulting DNA was eluted in 110 µl of elution 
buffer. 
 
2.2.4 Molecular techniques 
Multiplex PCR was performed for tcdA, tcdB, cdtA, cdtB and 16s rDNA, according to the 
method of Persson et al. (2008). After the initial results showed weak bands for detection of 
toxin genes from some isolates the method was changed to a monoplex PCR for the 
detection of tcdC and 16S rDNA and 2 plex PCR for the detection of the C. difficile toxin 
genes, tcdA and tcdB and for C. difficile binary toxin genes cdtA and cdtB. After the initial 
results showed that the 2 plex PCR in stool was unable to detect tcdA or tcdB from some 
stool samples the method was changed to a monoplex PCR. 
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Specific amplification of a segment of 16S rDNA was used as a positive control to 
determine whether non-specific inhibition of PCR reactions was occurring and to verify the 
quality of the genomic DNA template. Primers were manufactured by GeneWorks 
(Thebarton, Australia). A robotic pipette (Castrof 1200, QIAGEN) was used for loading the 
Master Mix and DNA to decrease pipetting errors that may occur with manual pipetting. 
  
2.2.4.1 Conventional PCR  
Conventional PCR for the detection of tcdA, tcdB, cdtA, cdtB, 16S rDNA and tcdC was 
performed to identify the presence of toxigenic and non-toxigenic C. difficile in stool 
samples using a Rotor-Gene 6000 (QIAGEN). 5 µl DNA extracted from isolated C. difficile 
colonies was used for the conventional PCR in a 50 µl reaction volume, which was 
composed of 5 µl buffer 2 (PE), 2.5 mM MgCl2, 16 µM dNTPs and 0.5 µM from each 
forward and reverse primers as described by Persson et al. (2008) and 2U of AmpliTaq 
Gold (Perkin Elmer). 
 
The conventional PCR for detection of C. difficile genes was also performed using DNA 
extracted directly from stool samples. A 50 µl reaction volume composed of 25 µl of 
HotStarTaq plus Master Mix (QIAGEN), 0.5 µM for each forward and reverse primers as 
described by Persson et al. (2008), 0.5 µl BSA and 20 µl of the genomic template DNA was 
used per reaction. The thermocycler conditions for the conventional PCR using isolate 
DNA were 10 min at 94°C, followed by 35 cycles of 50 s at 94°C, 40 s at 54°C and 50 s at 
72°C and a final extension of 3 min at 72°C. After the initial results showed some weak 
bands for detection of toxin genes from stool samples by conventional PCR, the annealing 
temperature and cycle number were modified from that reported by Persson et al. (2008) to 
give better reproducibility. The final cycling conditions for stool DNA were 10 min at 
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94°C, followed by 45 cycles of 50 s at 94°C, 40 s at 57°C and 50 s at 72°C, and a final 
extension of 3 min at 72°C. Amplification of tcdC was performed using isolate DNA with 
both forward and reverse primers as described by Persson et al. (2008) in a 50 µl reaction 
volume. The composition of the reaction was as described for testing isolate DNA for the 
above listed genes. Thermocycle conditions were 6 min at 94°C, followed by 35 cycles 
consisting of 50 s at 94°C, 40 s at 47°C and 50 s at 72°C, and a final extension at 72°C for 
3 min.  
 
The PCR products were separated on preformed 2% TAE agarose Egels (AMRESCO, 
Solon, USA) by electrophoresis using a gel dock. The gel was completely immersed in 
fresh room temperature TAE buffer, and 10 µl of PCR product from each PCR reaction was 
then mixed with 2.5 µl EZ-Vision® DNA Dye (AMRESCO, Solon, USA) as loading buffer 
and loaded sequentially into the wells. Marker VI DNA (Roche, Indianapolis, USA) was 
used in the first and last wells. A constant 130 volt charge was applied across the gel for 30 
min, and the resulting electrophoresis banding patterns were visualized under 280nm 
ultraviolet (UV) light. Each gel picture was recorded using Fluor-S tm MultiImager (Bio-
Rad, Hercles, USA). 
  
The PCR products obtained from amplification of tcdC were sequenced when the band size 
was less than the predicted 475 bp for wild-type isolates. Each isolate requiring sequencing 
was amplified 5 times as described above for tcdC detection (i.e. 5x50 ml PCR reactions 
per sample) to provide sufficient amounts of product for purification. Purification and 
concentration was performed using a Wizard PCR Preps DNA Purification System 
(Promega) according to the manufacturer’s instructions. Sequencing was performed by the 
Gandel Charitable Trust Sequencing Center (Monash Health Research Precinct, Melbourne, 
Australia) on an ABI Prism automated DNA sequences. On receipt of the sequences, 
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analysis was performed using Geneious (version 5.0.4) DNA analysis program (Biomatters, 
Auckland, New Zealand). 
 
2.2.4.2 Real-time PCR primer and probe design  
The primers and probes used in this study were modified from Wroblewski et al., (2009) 
after examining published sequences for target genes (Table 2.1). Primer and probe sets 
targeted C. difficile enterotoxin A gene (tcdA), cytotoxin B gene (tcdB), and binary toxin 
genes A and B (cdtA and cdtB) respectively. The modified primers and probes are presented 
in Table 2.1. An internal control (IC) was included during the QIAsymphony SP automated 
DNA extraction to monitor the efficiency of sample preparation and downstream assay. The 
DNA template used as an IC is a synthetic oligonucleotide derived to be unlikely to 
resemble existing bacterial sequences and is added into the specimen by the QIAsymphony 
SP prior to DNA extraction. The sequence for the IC was:  
GTCCTCACACCAGTTGCCGCGCAAAGTATGTGGAATGTTAACACACCCACACC 
ACACCCACACACGTGT TGGATC AATTTCGAGATGCGAGCTGCCAAGC. 
A negative result for the IC after PCR of samples indicates failure of DNA extraction (ruled 
out if DNA is visualised on electrophoresis) or amplification inhibition.  
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Table 2.1 Primer and probe sequences used in real-time multiplex PCR assay and Deletion assay (Δ117). The letters in the red colour are the modified 
nucleotides from Wroblewski et al. (2009). 
Target Sequence name Sequence (5′-3′)  Product length (bp) Region Reference 
tcdA CD-tcdA-F* CAGRGCTAATAGYTTGTTTACAGAACA 143 717-859 Wroblewski et al., 2009 
 CD-tcdA-R CAACATCTAAATATACTCCGCCAAAA   Wroblewski et al., 2009 
 CD-tcdA-MGB1* 5’d CAL Flour Red 610 GCAGCTAAATTYCCACGATTTAACAACTCCTGAYTATAA-BHQ-2 3’   Wroblewski et al., 2009 
      
tcdB CD-tcdB-F* AGCAGTTGAMTATAGYGGTTTAGTTAGAGTTN 144 6552-6695 Wroblewski et al., 2009 
 CD-tcdB-R* YTAGCTTTTTTAGTTTCTGGATYGAA   Wroblewski et al., 2009 
 CD-tcdB-MGB* 5’ d Quasar 705-CAWCCAGTYTCAATTGTATATGWTTCTCCA-BHQ-2 3’   Wroblewski et al., 2009 
      
cdtA CD-cdtA-F GATCTGGTCCTCAAGAATTTGGTT 103 1051-1153 Wroblewski et al., 2009 
 CD-cdtA-R GCTTGTCCTTCCCATTTTGATT   Wroblewski et al., 2009 
 CD-cdtA-MGB 5’ d FAM-AACTCTTACTTCCCCTGAAT-BHQ-1 3’   Wroblewski et al., 2009 
      
cdtB CD-cdtB-F AAAAGCTTCAGGTTCTTTTGACAAG 132 837-968 Wroblewski et al., 2009 
 CD-cdtB-R TGATCAGTAGAGGCATGTTCATTTG   Wroblewski et al., 2009 
 CD-cdtB-MGB* 5’ d CAL Fluor Orange 560 -CAAGAGATCCGTTAGTTGCAGCRTATCCAATTGT-BHQ-1 3’   Wroblewski et al., 2009 
      
tcdC(Δ117) CD-tcdC-F GCA CAA AGG RTA TTG CTC TAC TGG 70 83-152 de Boer et al, (2010) 
 CD-tcdC-R1 AGC TGG TGA GGA TAT ATT GCC AA   de Boer et al, (2010) 
 CD-tcdC-R2 CAA GAT GGT GAG GAT ATA TTG CCA   de Boer et al, (2010) 
 CD-tcdCwt-MGB 6FAM-AAA CAC RCC HAA AAT AA-NFQ-MGBNFQ   de Boer et al, (2010) 
 CD-tcdCmut-MGB VIC-AAA CAC RCC AAA ATA A-NFQ-MGBNFQ   de Boer et al, (2010) 
      
(IC) Internal Control-F GTG CTC ACACCAGTTGCCGC 100   
 Internal Control-R GCTTGGCAGCTCGCATCTCG    
  Internal Control-P 5’ [cy5]ATTGTGTGGGTGTGGTGTGGGTGTGTGC[BHQ3] 3’    
R=A or G; Y=C or T; M=A or C; N=G or A or T or C; W=A or T; H=A, C or T. 
* Primers/probes used modified from Wroblewski et al. (2009)
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2.2.4.3 Real-time multiplex PCR assay 
The real-time PCR assay was performed on a Rotor-Gene 6000 series 5 plex (QIAGEN) in 
a 72-well optical plate format. This machine has five fixed path lengths and a separate high 
intensity light-emitting diode (LED) excitation source and matching emission filter for five 
channels. Orange 585nM/610nM, Crimson 670nM/710Nm, Green 470Nm/510M, yellow 
530nM/555nM and Red 625nM/660nM channels were used for tcdA, tcdB, cdtA, and cdtB 
and Internal Control probes respectively. For testing of the isolates, each 26.5 µl reaction 
mixture consisted of 12.5 µl of mastermix (10 mM Tris-HCI, ph 8.3, 50 mM KCI, 2.5 mM 
MgCl2, 0.2 mM dNTP’s), 1.5 µM SYTO 9 dye (Invitrogen, CA, USA) and 0.025 U/ µl 
reaction volume AmpliTaq Gold DNA polymerase (Applied Biosystems, Life 
Technologies, CA, USA)) and 0.4 µM of each primer, 0.15 µM of each probe and 10 µl 
genomic DNA. Reactions were run under the following conditions: 50°C for 2 min, 95°C 
for 10 min, followed by 40 cycles of 95°C for 15 s, and 60°C for 1 min. Data was acquired 
and analysed with the Rotor-Gene 6000 series software (QIAGEN). PCR runs were 
analyzed using a fixed threshold of 0.05. A PCR run was considered valid when the no 
template control (NTC) was negative, and the IC was positive with a threshold cycle (Ct) of 
less than 40 cycles. A real-time PCR was considered inhibited when the Ct value for the IC 
exceeded 34.91 cycles (i.e. the mean Ct value for uninhibited specimens+2 standard 
deviations). 
 
2.2.4.4 Deletion assay (delta 117 detection) 
A delta 117 PCR assay (Δ117) (de Boer et al., 2010) for the detection of isolates carrying 
the Δ117 tcdC mutation was performed on extracted DNA from isolates and samples. The 
Δ117 assay utilizes two TaqMan MGB probes, a wild type (WT) probe and a mutant (MUT 
Δ117) probe respectively that both can hybridize with the part of the tcdC sequence that 
flanks the 1 bp deletion at position 117. Isolates that do not carry the 1 bp deletion will give 
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a stronger signal with the WT probe, while 027/NAP1 isolates will do so with the MUT 
Δ117 probe. The Δ117 PCR assay primer/probe set was used as described by de Boer et al. 
(2010) (Table 2.1).  
 
The Δ117 PCR assay was performed on 98 C. difficile (93 clinical isolates and five 
reference control strains) and 70 stool samples using TaqMan Genotyping Master Mix 
(QIAGEN). DNA used was from isolates and stools (manual extraction and robotic 
extraction). Each 20 µl reaction consisted of 5 ng of extracted DNA, 10 µl TaqMan 
Genotyping Master Mix (Applied Biosystems, Foster, USA) and 0.4 µM of each primer, 
0.1 µM of each probe. Reactions were run under the following conditions: 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 s, and 60°C for 1 min.  
The real-time TaqMan PCR deletion assay was carried out on the Rotor-Gene 6000 series 2 
plex (QIAGEN) with the use of scatter plotting software (QIAGEN) for analysis of results. 
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2.3 Results  
2.3.1 Analysis of Conventional PCR using isolates DNA  
All isolates were confirmed as C. difficile through colonial morphology, characteristic 
odour, Gram stain and CD Agglutination Test (OXOID). After the initial testing of the 
multiplex PCR showed some weak bands (Appendix A1) the method was changed to a 2-
plex PCR for the detection of the C. difficile toxin genes, tcdA and tcdB and for C. difficile 
binary toxin genes (cdtA and cdtB) and a monoplex PCR conducted for tcdC and 16S 
rDNA. All 93 clinical isolates produced a PCR product in the monoplex for 16s rDNA. All 
isolates producing a tcdA band also produced a tcdB band. PCR amplification results of 
tcdA and tcdB of 24 isolates are shown in Figure 2.2. The tcdA/tcdB bands for other isolates 
are presented in Appendix A (Figures A2, A3, A4, and A5). The number of isolates with 
toxin genes and combination of toxin genes is summarized in Table 2.2. 
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Figure 2.2 Amplification of tcdA (629 bp) and tcdB (410 bp) by 2-plex 
conventional PCR in 24 C. difficile isolates. Lane 1 is DNA marker VI (154-2176 
bp); lanes 2-25 representing C. difficile isolates number 01-24; lane 26 is a NTC. 
 
 
Amplification of cdtA and cdtB showed that seven isolates out of a total of 93 tested 
positive. It was not possible to show that both toxin genes were amplified because the band 
for cdtA was a similar size to that of cdtB and thus is shown as a single strong band (Figure 
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2.3). For the purpose of identifying the presence of binary toxin genes it was decided that 
the presence of a single strong band around 260 bp would be sufficient. The result of two 
positive isolates is shown in Figure 2.3. The cdtA/cdtB bands for other isolates are 
presented in Appendix A (Figures A6, A7, A8 and A9). 
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Figure 2.3 Amplification of cdtA (221 bp) and cdtB (262 bp) by 2-plex conventional 
PCR. Lanes 1 is DNA marker V (8-587 bp); lanes 2-25 representing C. difficile 
isolates number 25-48; lane 26 is a NTC. 
 
 
The results of tcdA, tcdB and binary toxin (cdtA and cdtB) detection by conventional PCR 
using isolate DNA on 93 isolates are summarised in Table 2.2 
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Table 2.2 Conventional PCR results for toxin genes in 93 clinical isolates. 
tcdA/tcdB cdtA/cdtB tcdC nucleotide Deletions 
(≥ 1 bp) 
tcdC stop codon at 
184 bp 
No. of isolates 
found 
- - - - 34 
+ - - - 50 
+ - 18 bp - 2 
+ + 54 bp - 1 
+ + 21 bp - 3 
+ + 39 bp + / -* 2 
+ + Δ117 and 18 bp - 1 
    Total 93 
* Both isolates have 39 bp deletions in tcdC but only one of them contained a C-T transition at 
position 184 bp. 
 
 As previously showed in materials and methods Figure 2.1 the toxin gene results of the 93 
isolates in Table 2.2 comes from 23 isolates forwarded from Austin Health and 70 isolates 
were from 70 stool samples from the Microbiology Department at Austin Health. The 
results of toxin genes for these 70 isolates where corresponding stool samples were also 
available to be tested represented in Table 2.3.  
 
Table 2.3 Conventional PCR results for toxin genes in 70 clinical isolates where stool was 
also available for later testing. 
CTA tcdA/tcdB cdtA/cdtB No. of isolates found 
+ + + 5 (7.2%) 
+ + - 24 (34.3%) 
+ - - 4 (5.7%) 
- - - 21 (30%) 
- + + 1 (1.4%) 
- + - 15 (21.4%) 
   
Total 70 
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From Table 2.3, PCR for tcdA/tcdB was in agreement with stool CTA in 71.5% of samples. 
In four samples cytotoxicity of stool was reported positive, yet the tcdA/tcdB results were 
negative. 22.8% of isolates were positive for tcdA/tcdB but were reported negative in 
cytotoxicity testing. 8.6% of the 70 isolates were binary toxin gene positive.  
 
PCR products obtained from the amplification of tcdC of 93 isolates showed an amplicon 
of around 475 in 84 (90.3%) isolates. Nine isolates (9.7%) (Isolates 12, 29, 39, 42, 53, 54, 
60, 68 and 78) showed a PCR product for tcdC of less than 475 bp. Figure 2.4 shows three 
of these isolates in lanes 6, 16 and 19. Results of the remaining isolates are shown in 
Appendix A (Figures A10, A11, A12 and A13).  
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Figure 2.4 Amplification of tcdC (475 bp) by conventional PCR. Lane 1 is DNA 
marker VI (154-2176 bp); lanes 2-25 representing C. difficile isolates number 25-
48; lane 26 is a NTC. 
 
 
Sequencing of tcdC was performed for seven isolates with PCR products less than the 
predicted 475 bp in wild-type isolates. Four isolates numbered as (01, 14, 31 and 55) with 
normal tcdC band size (475 bp) were also sequenced to compare with these seven isolates. 
The reference sequence DQ861418 was extracted from GenBank to use as a reference 
guide for alignment (Figure 2.5). Sequencing of these 11 isolates revealed that six isolates 
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contained gene deletions of 18, 21, 39 or 54 bp and that one of these isolates (isolate 
number 29 shown in Figure 2.5) contained a C – T transition at position 184 bp which 
would introduce a premature stop codon. The 39 bp deletion was observed in isolate 
number 29 (sequence Figure 2.5) and isolate number 42 (sequence Figure 2.5). An 18 bp 
deletion was observed in isolates number 39 (sequence Figure 2.5) and isolate number 68 
(sequence Figure 2.5). Isolate number 53 (sequence Figure 2.5) had a 21 bp deletion and 
isolate number 78 (sequence Figure 2.5) had a 54 bp deletion. Isolate number 12 was found 
to have a single nucleotide deletion at position 117 (Δ117 sequence Figure 2.5). This 
deletion has been described by MacCannell (2006) and introduces a frameshift that will 
result in a nonsense mutation at position 196 and a radical alteration in the preceding 26 
deduced amino acid residues. The predicted tcdC gene product is truncated from 232 to 65 
amino acid residues. This isolate also contained an 18 bp deletion between nucleotides 330 
to 347 which is identical to that previously described by MacCannell (2006) and 
characteristic of the 18 bp deletion in BI/NAP1/ribotype 027. 0923384942 
 
 
 
 
 
 
 
 
Figure 2.5 Comparison of tcdC nucleotide sequences obtained from sequenced 
PCR products of 11 isolates to the published sequence for the reference strain 
DQ861418. Grey lines and dashes indicate identical bases and deletions, 
respectively. Coloured lines in the sequenced PCR products (lines 3-13) indicate 
bases different to the consensus sequence listed at the top of the Figure. 
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2.3.2 Analysis of conventional PCR using stool DNA 
Conventional PCR using DNA extracted directly from 70 stool samples by QIAamp® 
DNA Stool Mini Kit (QIAGEN) was performed to detect C. difficile toxin genes tcdA/tcdB 
and cdtA/cdtB as well as 16S rDNA as an internal PCR control. The original annealing 
temperature of 54°C as reported in Persson et al. (2008) showed weak bands in initial 
testing. After further testing, 57°C was used for annealing. The result of the internal PCR 
control 16S rDNA was positive for all 70 stool samples. Results of tcdA of 23 stool samples 
are shown in Figure 2.6. Results of remaining isolates are shown in Appendix B (Figures 
B1and B2).  
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Figure 2.6 Amplification of tcdA resulting in a 629 bp product by conventional PCR 
using stool DNA. Lanes 1 and 26 are DNA molecular weight marker VI (154-2176 
bp); Lanes 02-24 representing stool samples number (1, 4, 5, 12, 13, 17, 18, 19, 22, 
25, 26, 27, 29, 31, 32, 35, 36, 37, 38, 39, 42, 43 and 51); lane 25 negative control. 
Results of tcdB of 23 stool samples are shown in Figure 2.7. Results of remaining isolates 
are shown in Appendix B (Figures B3 and B4).  
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Figure 2.7 PCR products from amplification of tcdB (410 bp) by conventional PCR 
using stool DNA. Lanes 1 and 26 are DNA molecular weight marker VI (154-2176 
bp); Lanes 02-24 representing stool samples number (1, 4, 5, 12, 13, 17, 18, 19, 22, 
25, 26, 27, 29, 31, 32, 35, 36, 37, 38, 39, 42, 43 and 51); lane 25 negative control. 
Many tcdB bands were lower in intensity than those obtained by tcdA PCR. However, tcdB 
PCR was able to detect a PCR product for sample number 29 (lane 14 Figure 2.7) whereas 
the tcdA PCR showed no band for this samples (lane 14 Figure 2.6). This sample was 
confirmed tcdA/tcdB positive in a repeat run.  
 
PCR for cdtA and cdtB was performed on the 70 stool DNA extracts. Clear separation of 
the PCR products was obtained as shown in Figure 2.8. The result of two positive isolates is 
shown in Figure 2.8. The cdtA/cdtB bands for other isolates are presented in Appendix B 
(Figures B5 and B6). 
 
 
 
 
 
 
   
2176  
1766  
 
1230  
1033  
 
653  
 
517  
453  
394  
298  
234  
 
154  
 46  
                     01    02    03    04    05    06    07    08    09    10    11    12    13    14    15     16   17   18   19    20    21   22    23    24   25   26 
 
Figure 2.8 Amplification of cdtA 221 bp products and cdtB 262 bp products by 
conventional PCR using stool DNA in 24 stool sample. Lanes 1 and 26 are DNA 
marker VI (154-2176 bp); lanes 2-25 representing stool samples number (1, 4, 5, 
12, 13, 17, 18, 19, 22, 25, 26, 27, 29, 31, 32, 35, 36, 37, 38, 39, 42, 43 and 51); lane 
26 is a NTC. 
The results of testing for tcdA/tcdB and cdtA/cdtB for the 70 stool samples is shown in 
Table 2.4 and compared to the CTA results reported on these stool samples. 
Table 2.4 PCR and CTA result of the 70 samples tested by conventional PCR using stool 
DNA 
CTA tcdA/tcdB cdtA/cdtB No. of samples found 
+ + + 4 (5.7%) 
+ + _ 26 (37.1%) 
+ _ _ 3 (4.2%) 
_ _ _ 25 (35.7) 
_ + + 1 (1.4%) 
_ + _ 11 (15.7%) 
 
From Table 2.4, PCR for tcdA/tcdB was in agreement with stool CTA in 78.5% of samples. 
In three samples cytotoxicity of stool was reported positive, yet the tcdA/tcdB results were 
negative. 17.1% of isolates were positive for tcdA/tcdB but were reported negative in 
cytotoxicity testing. 7.1% of the 70 isolates were binary toxin gene positive. 
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2.3.3 Validation of the use of stool sample for testing of C. difficile toxin genes by PCR 
To improve the speed of diagnostic testing for C. difficile it is important to be able to 
validate that testing for toxin genes on stool samples performs as well as testing on isolates. 
The results of 70 stool samples tested for tcdA, tcdB and binary toxin (cdtA and cdtB) by 
conventional PCR assay using DNA extracted from pure culture were compared to the 
results obtained by testing from the same stool using the same primers and DNA extracted 
directly from the same stool samples. The results showed that the 37 stool samples positive 
by conventional PCR using stool DNA were also positive by conventional PCR using 
isolate DNA. Twenty isolates were negative by conventional PCR using isolate DNA were 
also confirmed negative by conventional PCR using stool DNA (Table 2.5). The 
conventional PCR using DNA extracted directly from stool sample was positive in 5 
additional samples and 8 samples were false negatives. If we use the PCR of isolate DNA 
as the gold standard then the sensitivity and specificity of the PCR on stool DNA is 82% 
and 80% respectively. 
 
Table 2.5 Comparison of conventional PCR (stool DNA) with conventional PCR (isolate 
DNA) 
Assay  
No. of 
samples 
included  
Results  PCR(isolate DNA)  Sensitivity (%)  
Specificity 
(%)  
   Positive   Negative   
PCR (stool 
DNA)  70  
Positive  
Negative  
37               5  
 8                20  
82%  80%  
 
 
Interestingly, although PCR of stool DNA failed to detect toxin genes in eight samples that 
were positive by testing isolate DNA, a similar number (5) were found to be positive in 
stool DNA but negative by testing isolates for toxin genes. Since testing of stool DNA had 
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values not less than 80% for both sensitivity and specificity, it was decided that this would 
be the benchmark to compare the performance of real-time PCR. 
2.3.4 Analysis of multiplex real-time PCR assay using stool DNA 
A multiplex real-time PCR assay for detection of C. difficile toxin genes tcdA, tcdB, cdtA 
and cdtB was performed on a Rotor-Gene 6000 series 5 plex (QIAGEN) in a 72-well 
optical plate format using DNA extracted directly from 70 stool samples by QIAsymphony 
SP automated systems (QIAGEN). The results of 45 samples tested by this assay for 
detection of tcdA, tcdB, cdtA and cdtB are shown in Figures 2.9, 2.10, 2.11 and 2.12 
respectively. Results of the remaining samples (46 – 70) are shown in Appendix C (Figures 
C1, C2, C3 and C4). The internal control was positive in all 70 stool samples and the Ct 
value for the IC for all samples was less than 34.91 as shown in Appendix C (Figures C5 
and C6). The toxin gene profile of these 70 stool samples detected by this assay is 
summarized in Table 2.6 and is compared to the result of cytotoxicity testing of stool. There 
was complete agreement between the 50 samples that were tcdA positive and tcdB positive 
by real-time PCR. This was also found for the six samples positive for cdtA and cdtB. The 
mean Ct value for tcdB (Figure 2.10) was 29.36 (SD = 3.8) which was higher than the Ct 
value for tcdA which was 26.4 (SD = 3.8) (Figure 2.9). 
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Figure 2.9 Amplification of tcdA for samples 1-45 by multiplex real-time PCR. 
Red curves were tcdA positive samples while the green lines were tcdA 
negative samples. 
 
Figure 2.10 Amplification of tcdB for samples 1-45 by multiplex real-time 
PCR. Red curves refer to tcdB positive samples while the green lines were 
tcdB negative samples. 
Six samples positive for tcdA and tcdB were also positive for cdtA and cdtB. The mean Ct 
value for cdtA (Figure 2.11) was 29.66 (SD=2.5) which was higher than the mean Ct value 
of 27.66 (SD=1.6) for cdtB (Figure 2.12). 
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Figure 2.11 Amplification of cdtA for samples 1-45 by multiplex real-time 
PCR. Red curves refer to cdtA positive samples while the red and green lines 
were cdtA negative samples. 
 
 
 
Figure 2.12 Amplification of cdtB for samples 1-45 by multiplex real-time 
PCR. Red curves refer to cdtB positive samples while the red and green lines 
were cdtB negative samples. 
 
 
The genetic profile of 70 stool samples tested by multiplex real-time PCR that also had a 
cytotoxicity reported is shown in Table 2.6. 
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Table 2.6 PCR and CTA result of the 70 samples tested by multiplex real-time PCR assay 
using stool DNA 
CTA tcdA/tcdB cdtA/cdtB No. of sample found 
+ + + 5 (7.1%) 
+ + - 27 (38.6%) 
+ - - 1 (1.4%) 
- - - 19 (27.1%) 
- + + 1 (1.4%) 
- + - 17 (24.3%) 
   Total 70 
 
PCR for tcdA/tcdB was in agreement with stool CTA in 72.8% 0f samples. In one sample 
cytotoxicity of stool was reported positive, yet the tcdA/tcdB results were negative. 25.7% 
of isolates were positive for tcdA/tcdB but were reported negative in cytotoxicity testing. 
8.5% of the 70 isolates were binary toxin gene positive. Of the 70 stool samples growing C. 
difficile, 33 were positive in the CTA (Table 2.6). The multiplex real-time PCR assay 
agreed with 32 of these samples and the one negative was also negative by conventional 
PCR of both stool and isolate DNA. The real-time PCR identified a further 18 faecal 
samples that were tcdA and tcdB positive of which all were confirmed positive by 
conventional PCR.   
  
2.3.5 Validation of multiplex real-time PCR assay with faeces from patients suspected 
of CDI 
To evaluate the applicability of multiplex real-time PCR for detection of toxigenic C. 
difficile in stool, 70 stool samples tested for tcdA, tcdB and binary toxin (cdtA and cdtB) by 
conventional PCR assay were compared to the results obtained by DNA extracted directly 
from the same stool sample by the automated system (QIAsymphony). The results showed 
that the 42 samples (Table 2.7) detected positive by multiplex real-time PCR were also 
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positive by conventional PCR using stool DNA and 20 isolates were negative by multiplex 
real-time PCR were also confirmed negative by conventional PCR using stool DNA (Table 
2.7). The multiplex real-time PCR was positive in eight additional samples and no false 
negatives were detected for stool testing by real-time PCR. These eight samples were 
previously reported as negative for toxin genes when DNA was extracted manually from 
stool. 
 
Table 2.7 Comparison of multiplex real-time PCR with conventional PCR (stool DNA) 
Assay  
No. of 
samples   
included  
Results  Conventional PCR stool DNA  
Sensitivity 
(%)  
Specificity 
(%)  
   Positive      Negative   
Multiplex 
RT-PCR 
(stool DNA)  
70  
Positive  
Negative  
42               8  
 0               20 
100%  71.4%  
 
The overall agreements of the multiplex real-time PCR and the conventional PCR using 
stool DNA were 100% sensitivity and 71.4% specificity (Table 2.7). 
 
The result of real-time PCR testing of stool was compared to conventional PCR testing of 
isolate DNA (Table 2.8). Using the conventional PCR (isolate DNA) as a gold standard the 
sensitivity and specificity were 100% and 80% respectively. 
Table 2.8 Comparison of multiplex real-time PCR with conventional PCR (isolate DNA) 
Assay  
No. of 
samples   
included  
Results  Conventional PCR isolate DNA  
Sensitivity 
(%)  
Specificity 
(%)  
   Positive    Negative   
Multiplex 
RT-PCR 
(stool DNA)  
70  
Positive  
Negative  
45              5  
  0               20 
100%  80%  
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From Table 2.8, five stool samples gave positive toxin PCR results but the corresponding 
isolates from the same stool were not found to be PCR-toxin gene positive. 
 
2.3.6 Sensitivity and specificity of multiplex real-time PCR assay 
The multiplex real-time PCR assay was more sensitive than conventional PCR in 
comparison with the gold standard method of CTA (Table 2.9).  
 
Table 2.9 Comparison of two conventional PCR and multiplex real-time PCR with gold 
standard CTA 
Assay  
No. of 
samples   
included  
Results  CTA Assay(no.)  Sensitivity (%)  
Specificity 
(%)  
   Positive    Negative   
PCR (isolate 
DNA)  70  
Positive  
Negative  
29      16  
4        21  
87.8%  56.8%  
PCR (stool 
DNA)  70  
Positive  
Negative  
28      11  
5        26  
84.8%  70.2%  
Multiplex 
RT-PCR 
(stool DNA)  
70  
Positive  
Negative  
32      18  
1        19  
97%  51.4%  
 
DNA extracted from stool using manual kit was used for conventional PCR detection of 
toxin genes in stool. DNA extracted from stool using the robotic platform was able to detect 
all the positive stool samples found by manual DNA extraction. An additional eight out of 
50 (16%) samples were found to be positive with robotic extraction of DNA.  
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2.3.7 Deletion assay (delta 117 detection) 
A PCR assay for the Δ117 mutation (de Boer et al., 2010) was performed on all isolates and 
stool samples DNA using the three DNA extraction methods described previously. The 
real-time PCR for tcdC gave a mean value of 26.9 (SD=2.9) (Figure 2.13) which was 
comparable to the Ct value obtained by de Boer et al., (2010).  
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Figure 2.13 Amplification of tcdC for samples 1-45 by multiplex real-time PCR. 
Red curves were tcdC positive samples while the green lines were tcdC negative 
samples. 
 
 
The real-time PCR data was imported to scatter plotting software which showed four 
clusters (A, B, C and D, Figure 2.14). In Figure 2.14, DNA was extracted from pure 
culture. The wild-type probe was detected on the green channel whereas the mutant probe 
was on the yellow channel. As expected the strongest reading for the yellow channel was 
the control isolates for Δ117 (Figure 2.14, cluster C). Isolates that had the predicted wild-
type tcdC genotype were clustered together (A). Those with some base pair variation 
clustered in B and the control isolates for Δ117 and one clinical isolate clustered together in 
C. Isolates where no tcdC gene product was produced clustered together as group D. 
 
 
Cycle  
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Figure 2.14 Delta 117 assay used DNA extracted from pure culture. A: 
no sequence variation, B: 117 (A/C) and 120 (C/T), C: Delta 117, D: no 
tcdC detected. X axis signal from mutant probe, Y axis signal from wild-
type probe. 
 
 
To see if similar clusters were obtained by direct testing from stool, scatter plotting 
software was used to analyse the real-time PCR data obtained from stool DNA using a 
manual kit. Similar clusters were obtained to Figure 2.14 and are shown in Figure 2.15. 
 
Figure 2.15 Delta 117 assay used DNA extracted directly from stool 
samples using QIAamp® DNA Stool Mini Kit A: no sequence 
variation, B: 117 (A/C) and 120 (C/T), C: stool sample 12 confirmed 
as Δ117, D: no tcdC detected. 
 
 
To see if an automated robotic platform performed as well as manual extraction of DNA, 
scatter plotting software was used to analyse the real-time PCR data obtained from stool 
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DNA using the robotic extraction method. Similar clusters were obtained to Figure 2.15 and 
are shown in Figure 2.16. 
 
Figure 2.16 Delta 117 assay used DNA extracted directly from stool 
samples using QIAsymphony SP automated systems A: no sequence 
variation, B: 117 (A/C) and 120 (C/T), C: stool sample 12 confirmed as 
Δ117, D: no tcdC detected. 
The Δ117 PCR assay detected the tcdC Δ117 mutation in 1 of 70 samples (Cluster C, 
Figure 2.14, 2.15 and 2.16) and all four positive control isolates (Figure 2.14). The presence 
of hypervirulent C. difficile in one of the samples tested was confirmed by PCR-ribotyping 
of the isolate (Chapter 3) which showed an identical ribotyping pattern to the control 027 
strains. Sequencing of the tcdC PCR product confirmed the presence of the Δ117 mutation 
consistent with 027 strains (Figure 2.5, isolate 12). Sequencing of isolates clustering in 
groups A, B and C show why they cluster in different groups. As expected, the strongest 
ratio for the green/yellow channel was obtained by isolates most similar to the wild-type. 
Isolates differing by one base pair from the wild-type gave stronger signals with the yellow 
channel and isolates matching the wild-type gave the weaker yellow channel signals. 
Isolates without tcdC gave weak signals with both probes and were in a separate cluster. 
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2.4 Discussion 
PCR testing of toxin genes for the detection of C. difficile is recognised as rapid, sensitive 
and specific, however is yet to be widely used as a standalone test (Cohen et al., 2010). In 
the current study, conventional PCR using DNA extracted directly from stool samples gave 
a sensitivity of 82% and specificity of 80% when compared to conventional PCR using 
DNA extracted from pure culture. When DNA was extracted from stool using the robotic 
system, all samples detected as positive using the manual extraction method were found to 
be positive with an additional eight samples being positive. These corresponding eight 
samples detected negative by conventional PCR using stool DNA when compared to 
conventional PCR using isolate DNA.  
 
It would be expected that stool extraction would have a lower sensitivity compared to 
isolate DNA as there would be inhibitors present in stool. The fact that the robotic system 
identified eight samples more than the manual kit would seem to indicate that this system of 
DNA extraction was able to either overcome some of the inhibitors present in stool or 
extract DNA of better quality for testing. This finding was supported by the high sensitivity 
(100%) of multiplex real time PCR using robotic DNA when compared to conventional 
PCR. This supports the conclusion that real-time PCR performs as well as conventional 
PCR for testing of stool DNA. 
 
Five samples testing tcdA and tcdB positive by PCR using DNA extracted directly from 
stool samples by two DNA extraction methods (manual kit and QIAsymphony automated 
system) were not found to have isolates that were toxin positive. This may be explained if 
different types of C. difficile strains are present in the same stool sample. This finding has 
been reported by Wroblewski et al. (2009) when they showed that more than one strain can 
be present in a given stool sample. 
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The sensitivity of multiplex real-time PCR when compared to CTA was 97% (Table 2.9). 
This result was similar to that reported by de Boer et al. (2010) who showed a sensitivity of 
100% for the diagnosis of CDI using CTA as the “gold standard”. The high sensitivity 
obtained for the multiplex real-time PCR may be related to the use of the QIAsymphony SP 
automated system for extraction of DNA directly from stool samples. In a study published 
by Stamper et al. (2009b) using anaerobic toxigenic bacterial culture, as the “gold 
standard,” and DNA extracted by automated system (NucliSENS easyMAG platform) the 
sensitivity and specificity for ProGastro Cd assay (which is a new commercial TaqMan 
PCR assay that detects tcdB) were 77.3% and 99.2% respectively and for Wampole TOX-B 
test (a cell culture cytotoxicity neutralization assay (CCCNA)) were 63.6% and 99.2% 
respectively (Stamper et al., 2009b). The conclusion was that real-time PCR using DNA 
extracted by an automated system was superior to CTA for diagnosis of C. difficile 
infection. 
 
Detection of tcdA and tcdB by multiplex real-time PCR using our modified primers and 
probes derived from Wroblewski et al. (2009) showed that the tcdB had a higher Ct value 
than tcdA. Wroblewski et al. did not report the Ct values obtained in their assay. To 
improve the Ct values for tcdB it might be possible to revisit the design of the tcdB primers 
and probes which may lead to improved performance of the tcdB real-time assay. Despite 
the high sensitivity of the multiplex real-time PCR, the test showed a specificity of (51%) 
when using CTA as a gold standard. This is most likely due to the large number of ‘false’ 
positives (18 out of 70 samples, Table 2.9). The determination of false positives is reliant 
on how good the ‘Gold standard’ is and it has been shown that the CTA test has poor 
sensitivity compared to CTA determined by cytotoxic culture technique (Stamper et al., 
2009b). A similar study stated that using CTA testing was unreliable for detection of C 
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difficile (Eastwood et al., 2009). As the purpose of the current study was to validate that 
real-time PCR performed as well as conventional methods and that the robotic system was 
able to identify positive stool samples, future validation studies should be compared to the 
better gold-standard of cytotoxic culture.  
 
Although the contribution of binary toxin genes to the virulence of C. difficile strains 
causing infections is still poorly understood, the highly related binary toxin in Clostridium 
spiroforme has been implicated as a virulence factor as it has been shown to be involved in 
the pathogenesis of intestinal disease in rabbits (Geric et al., 2003). The prevalence of 
binary toxin-positive, A_ B_ strains has been reported at 2.0% (8 of 402) in one study (Geric 
et al., 2003). In our study we did not isolate any binary toxin positive tcdA-tcdB- strains, 
however since these strains do occur it would seem important to include testing for 
cdtA/cdtB genes.  
 
TaqMan based real-time PCR using the three different methods of DNA extraction 
identified the tcdC Δ117 mutation. However, the real-time PCR using DNA extracted by 
the automated system detected the tcdC Δ117 mutation in a shorter time compared to the 
other two extraction methods. This study is the first to use scatter plotting software to 
analyse Δ117 real-time PCR results. The use of scatter plotting software was able to 
identify an isolate and corresponding stool sample containing the epidemic 027/NAP1 
strain. In Figure 2.14, the control strains and isolate 12 cluster together with the strongest 
yellow channel signal. However the wild-type isolates with single base transition also 
cluster close by (Cluster B, Figure 2.14). Pure wild-type strains with tcdC also clustered 
with strong signals for both the green and yellow channels. The strongest signal for the 
mutant probe (yellow channel) was obtained in stool samples for the sample shown to 
contain isolate 12. To confirm the usefulness of the Rotor-gene scatter plotting software to 
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identify stools containing 027 ribotype strains, more clinical isolates would be need to be 
investigated. Our study support the results obtained by de Boer et al. (2010), that a TaqMan 
based real-time PCR assay is able to detect the tcdC Δ117 mutation without the need for 
melting curve analysis (de Boer et al. 2010). Testing for Δ117 on all samples positive for 
tcdA, tcdB, cdtA and cdtB would seem to be an effective way to identify patients with 027 
infection and help minimise the spread of the epidemic strain in hospitals and healthcare 
facilities. 
 
In conclusion multiplex real time PCR for detection of C. difficile toxin genes tcdA and 
tcdB as well as binary toxin cdtA and cdtB using DNA extracted by an automated system 
has been shown to give reliable results when compared to CTA and conventional PCR. 
Including binary toxin testing would seem to be important especially as tcdA_ tcdB_ binary 
toxin positive isolates have been reported. Furthermore, the Δ117 PCR may provide 
valuable information for quickly identifying 027 isolates so that the spread of epidemic C. 
difficile PCR ribotype 027 may be brought under control. 
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CHAPTER 3 
Development of an RT-PCR ribotyping technique 
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3.1 Introduction  
The methods used to type Clostridium difficile have been reviewed in Chapter one. The 
main methods used around the world are REA of the total bacterial genome (Kato et al., 
1993, Kuijper et al., 1987), PFGE, AP-PCR (Fawley and Wilcox, 2002, Killgore and Kato, 
1994, Rodriguez-Palacios et al., 2007), and PCR-ribotyping developed by Kostman et al. 
(1992). PCR-ribotyping was adapted by Gurtler (1993) for typing of C. difficile. PCR-
ribotyping produces multiple PCR products due to the presence of several alleles of the 
rRNA operon differing by the length of the ISR located between the 16S and the 23S rRNA 
genes.   
 
The single most important epidemic strain causing CDAD in North America and Europe 
types as BI by REA, North American (NA) pulsed-field type 1 (NAP1) by PFGE, and 027 
by PCR-ribotyping (BI/NAP1/027) (Kuijper et al., 2006, McDonald et al., 2005, Pepin et 
al., 2004). Restriction endonuclease analysis of the total bacterial genome is highly 
discriminatory but is still a crude method. PFGE may require up to 6 days to complete. 
PCR-ribotyping has been reported to provide a discriminatory, reproducible, and a simple 
alternative to other typing methods (Cartwright et al., 1995). This technique has a number 
of advantages over other methods; specifically, PCR-ribotyping has been shown to be more 
discriminatory than arbitrarily primed PCR (Collier et al., 1996), and is quicker and simpler 
than PFGE. PCR-ribotyping also avoids the excessive endogenous nuclease activity of 
some C. difficile isolates that renders them untypeable by PFGE (Stubbs et al., 1999). The 
emergence of the hypervirulent strain has increased the need for rapid typing of C. difficile. 
Despite the advantages of the PCR-ribotyping method it still requires analysis of 
electrophoretically separated bands and analysis using GelCompar software. Faster typing 
techniques will enable the quicker detection of hypervirulent strains and the timely 
implementation of infection control strategies. 
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A new technique known as high resolution melt (HRM) analysis can be used to characterize 
DNA samples according to their dissociation behaviour as they transition from double 
stranded DNA (dsDNA) to single stranded DNA (ssDNA). The melt characteristics of PCR 
products depends on GC content, length, sequence and heterozygosity and is best 
monitored with saturating dyes that fluoresce in the presence of double-stranded DNA with 
increasing temperature (Reed et al., 2007). Real-time PCR instruments that are equipped to 
perform HRM do so by acquiring data at small temperature increments such as 0.02°C. 
This enables the melt curve to be resolved with much greater power. HRM analysis can be 
used to detect single base sequence variations such as SNPs (single nucleotide 
polymorphisms) (Figure 3.1) or to discover unknown genetic mutations. It may be possible 
to analyse the pattern of different alleles produced by PCR-ribotyping through HRM 
analysis. 
 
The aim of this chapter is to develop a C. difficile real-time PCR typing method based on 
the HRM analysis of PCR products obtained from the ISR of C. difficile. This technique 
will then be compared to ribotyping for its discriminatory power.   
 
 
      Figure 3.1 DNA Melt Curve for High Resolution Melting Analysis. 
The research questions we aimed to answer in this part of the study were: 
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1- Can HRM analysis be used to identify clusters of related isolates including PCR ribotype 
027? 
2- Can the development of a RT-PCR-ribotyping technique lead to a quicker and cost 
effective screening of epidemic strains? 
3- Can HRM PCR-ribotyping be performed directly from stool? 
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3.2 Materials and Methods 
 
3.2.1 Bacterial isolates 
A total of 93 C. difficile isolates were collected as detailed in section 2.2.1. Five control 
strains were used as outlined in 2.2.1. 
 
3.2.2 DNA extraction 
The same DNA extracted from isolates and stool samples as detailed in sections 2.2.2 and 
2.2.3 was used in this study.  
 
3.2.3. Conventional PCR-ribotyping (ISR amplification) 
All isolates were typed using the PCR-ribotyping method described by Bidet et al. (1999). 
Briefly, amplification reactions were performed in 50 µL reaction volumes, composed of 5 
µL of buffer 2 (PE), 2.5 mM MgCl2, 16 µM dNTPs, 0.5 µM of both forward and reverse 
primers, 2U of AmpliTaq Gold (Perkin Elmer, Cetus, USA) and 5 µL of the genomic 
template DNA or 5 µL sterile water as a negative control. Amplifications were carried out 
in a GeneAmp PCR system 2700 for 1 cycle of 10 minutes at 94ºC; 35 cycles of 94ºC for 1 
min, 50ºC for 1 min, and 72ºC for 1 min; followed by a final extension cycle of 10 min at 
72ºC. Amplification products were fractionated by electrophoresis using polyacrylamide 
gel (Bio-Rad, Hercules, USA) 15% TBE (Tris-borate- EDTA) buffer (Eurobio, Les Ulis, 
France) to give more resolution of banding patterns. Ten µl of PCR product from each PCR 
reaction was then mixed with 2.5 µl loading buffer and loaded sequentially into the wells. 
Marker VI DNA (Roche, Indianapolis, USA) was used in the first and last wells. A constant 
200 volt (6.0V/cm) charge was applied across the gel for 90 min in 0.5 X TBE buffer and 
analysed under 280 nm ultraviolet (UV) light after staining for 20 min with 0.5 µg/µl 
ethidium bromide. Gel images were acquired by Fluor-S tm MultiImager (Bio-Rad) and 
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saved as high-resolution TIFF files. Gel images were saved as TIFF files and transferred to 
GelCompar II software V4.0 (Applied Maths, Austin, USA) to analyse band patterns. Each 
gel was standarised using a band tolerance of 0.5%. Cluster analysis was performed using 
Pearson coefficient with arithmetic (UPGMA) mean.  
 
3.2.4 Real-time PCR with HRM analysis 
Real-time PCR and HRM were performed in duplicate in a Rotor-Gene 6000 (QIAGEN). 
As good reproducibility was obtained with duplicates, all isolates were measured from then 
on singly to obtain all HRM profiles in a single run (maximum capacity for a single run is 
100 samples). The primer sequences used for the real-time PCR assay were the same 
primers as used in the conventional PCR ribotyping. All PCR mixtures (50 µL) contained 
5µL of buffer 2 (PE), 2.5 mM MgCl2, 16 µM dNTPs, 0.5 µM of both forward and reverse 
primers, 2U of AmpliTaq Gold (Perkin Elmer), 1.5 µL of 1 X SYTO-9 intercalating dye 
(Invitrogen) and 5 µL of the genomic template DNA (or sterile water as a negative control). 
The thermocycling consisted of an initial incubation at 50°C for 2 min and 1 cycle of 95°C 
for 10 min, followed by 45 cycles of 95°C for 5 s and 60°C for 60 s, with data acquired on 
the 60°C step in the green channel. The PCR HRM analysis was performed by heating the 
amplicon DNA gradually from 80°C up to 90°C in 0.1 increments in order to generate a 
melt curve. Raw melting-curve data was normalized for the 83 isolate and 5 reference 
controls by setting the pre-melt (initial fluorescence) and post-melt (final fluorescence) 
signals of all samples to uniform values. Pre-melt signals were uniformly set to a relative 
value of 100%, while post-melt signals were set to a relative value of 0%. The second step 
was to determine a temperature along the x axis of the normalized melting curves at which 
point the entire double-stranded DNA is completely denatured. The third step was to further 
analyze the differences in melting-curve shapes by subtracting the curves from a reference 
curve (also called the ‘base curve’), thus generating a difference plot curve, which helps to 
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cluster samples into groups that have similar melting curves (i.e., those with the same 
genotype). The final step was to generate the difference graph using the curve from 
ribotype 027 R20291 reference strain to analyse how close or different the isolates were to 
the ribotype 027 strain.  
 
3.2.5 Real-time PCR with HRM analysis using DNA extracted from stool   
Real-time PCR with HRM was repeated as described in section 3.2.4 using DNA extracted 
directly from 21 stool samples by QIAamp® DNA Stool Mini Kit (QIAGEN) to check if 
similar clusters could be identified directly in stool samples. 
  
3.2.6 ScreenClust analysis 
Clustering analysis was performed with a prototype version of the ScreenClust software 
(QIAGEN, Hilden, Germany). Raw HRM data from the Rotor-Gene operating software 
was imported into ScreenClust software. To determine differences between individual 
samples, normalized melt curves are first differentiated in ScreenClust. The HRM curves 
are derived by selecting two normalized regions, the first occurring prior to the melting of 
the double-stranded product and the second following complete separation of the two 
strands. Each region is generated by default by the software but may be manipulated 
manually to achieve optimum results. Default settings were used for the analysis. These 
regions function to normalize the fluorescence of the melt curves from the raw channels by 
averaging all starting and ending fluorescence values such that the end point value of each 
sample is identical to the average. This allows for the melting curve profile of each isolate 
to be analyzed relative to those of the others. Following this, a residual plot is generated by 
subtracting all the differentiated curves by the composite median of all curves. The residual 
plot is used as the data basis to form the principal component analysis that extracts a range 
of characteristics for each curve. The software enables a supervised mode which is used for 
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classification of unknown samples into known groups using known samples as controls and 
unsupervised mode is used to find de novo data groups when there is no prior knowledge 
on the number and kind of genotypes present in the data set. The classification of clusters of 
isolates was performed in unsupervised mode as no controls for each individual clusters 
were available. After the initial analysis, a cluster of 12 isolates contains the 027 strains was 
present, so the data was then analysed in supervised mode using the R20291 ribotype 027 
strain as a control. No template controls (NTC) and samples showing Ct values greater than 
25 on real-time PCR were removed from the analysis as a lack of melt curve features from 
weak PCR products affects the normalization.  A Ct value of 25 was selected as isolates 
with Ct values above 25 were also found to have correspondingly weak ribotyping bands 
produced that did not enable them to be accurately ribotyped. 
     
3.2.7 Discriminatory power measurement  
The discriminatory power of a typing method is its ability to distinguish between unrelated 
strains. Simpson's index of diversity was used based on the probability that two unrelated 
strains sampled from the test population will be placed into different typing groups (Hunter 
and Gaston, 1988). To assess the ability of HRM using ScreenClust software for data 
analysis to type isolates the discriminatory power was calculated by Simpson's index of 
diversity (Hunter and Gaston, 1988) and compared to the discriminatory power of 
conventional PCR-ribotyping of the same groups of isolates. 
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3.3 Results 
3.3.1 PCR ribotyping 
A total of 93 C. difficile clinical isolates and five references strains (ATCC 9689 and four 
C. difficile ribotype 027 strains) were analysed using PCR ribotyping. The PCR-ribotyping 
patterns of seven clinical isolates and four ribotype 027 reference strains (KI, R20291, 
M7404 and CD196) are shown in Figure 3.2. The results of remaining isolates are shown in 
Figure 3.3. Control isolate M7404 from the Canadian outbreak shows a different banding 
pattern but is still sufficiently similar to the other 027 control strains to cluster with them 
after UPGMA analysis (Figure 3.3). 
 
               M     01      02     03     04      05      06     07      08      09     10      11    M 
 
Figure 3.2 Representative PCR ribotype profiles from C. difficile; lanes 01-
06 representing C. difficile isolates number 89-94; lanes 07-10 C. difficile 
ribotype 027 controls 95, 97, 96 and 98; (KI, M7404 R20291 and CD196) 
respectively. Lane 11 C. difficile clinical isolate number 12 suspected as 027 
ribotype strain. M indicates molecular marker VI (154-2176 bp). 
 
 
Clinical isolate numbers 21, 23, 43, 45, 73, 79, 82, 83, 89 and 94 produced weak ribotyping 
patterns on polyacrylamide gel electrophoresis and Ct values greater than 25 on real-time 
PCR, so these isolates were excluded from GelCompar II analysis. The diversity of 83 C. 
difficile clinical isolates from patients at the Austin Hospital is illustrated by the UPGMA 
dendrogram (Figure 3.3). After considering the similarity in banding patterns 18 groups 
were found at 70% homogeneity using Person coefficient with UPGMA mean (Figure 3.3). 
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Figure 3.3 C. difficile ribotyping UPGMA dendrogram showing the ribotype patterns 
obtained by classic polyacrylamide gelelectrophoresis (dendrogram continued on next 
page).Coloration of isolate numbers relates to cluster groups outlined in section 3.3.3. The 
numbers in the dendrogram indicates the organism groups having a 70% similarity. 
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Figure 3.3 Continued C. difficile ribotyping UPGMA dendrogram showing the ribotype 
patterns obtained by classic polyacrylamide gel electrophoresis. Coloration of isolate 
numbers relates to cluster groups outlined in section 3.3.3. The numbers in the dendrogram 
indicates the organism groups having 70% similarity. 
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Four pairs of isolates 26 and 27, 53 and 54, 55 and 58, 96 and 98 showed 100% identity 
(Figure 3.3). Clinical isolate number 12 represented in lane number 11 of Figure 3.2 was 
identified as 027 ribotype because it showed 100% identity with the 027 ribotyping 
reference strains (KI, R20291 and CD196). The toxin profile listed in Figure 3.3 also shows 
it to have a profile consistent with 027 strains i.e. tcdA, tcdB, cdtA, cdtB and tcdC all 
positive. 
 
3.3.2 HRM data analysis 
Real-time PCR and HRM analysis were performed in duplicate on a Rotor-Gene 6000 
(QIAGEN). A total of 93 C. difficile clinical isolates and five references strains (ATCC 
9689 and four C. difficile ribotype 027 strains) had real-time PCR performed using the 
ribotyping primers. Clinical isolate numbers 21, 23, 43, 45, 73, 79, 82, 83, 89 and 94 
produced Ct values greater than 25 for real-time PCR and were excluded from HRM 
analysis due to the weak melting profiles. These isolates also produced weak ribotyping 
patterns on polyacrylamide gel electrophoresis, as reported in section 3.3.1. HRM 
normalization was performed on the remaining 83 isolates and five reference strains and is 
shown in Figure 3.4. 
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Figure 3.4 HRM normalized graph for (A) 83 C. difficile clinical isolates and 
five control strains and (B) four ribotype 027 reference strains and C. difficile 
clinical isolate number 12. Isolate 97 (M7404) in (B) shows a slightly different 
melt curve consistent with the differences found in the ribotype pattern in 
Figure 3.3. 
In Figure 3.4B it can be seen how closely clinical isolate number 12’s melt curve 
corresponds with that of ribotype 027 strains R20291, KI, and the historical strain CD196 
while the M7404 Canadian reference strain has a slightly different melt curve as shown in 
Figure 3.4B.  
The melt peak curves for 83 isolates and five reference strains are shown in Figure 3.5A. In 
Figure 3.5B the melt peak curves are shown for the control strains and isolate 12. The 
signal strength is weaker for isolate 12, however the shape of the curve is very similar to 
that of the control strains except for control strain 97 (M7404). As expected from the melt 
A  
B  12, 95, 96, 98  
97  
Temperature (°C)  
 
Temperature (°C)  
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curve, M7404 shows a different peak curve to the other control isolates. The number of 
peaks present is to be expected as PCR-ribotyping produces a number of PCR products. 
 
 
 
 
 
 
 
 
 
Figure 3.5 HRM melt peak analysis for (A) 83 C. difficile clinical isolates and 
5 control strain (B) four ribotype 027 reference strains and C. difficile clinical 
isolate number 12. 
A difference curve was constructed by subtracting the melt curve variance at each 
temperature from the control strain R20291 (isolate 96). These differences curves for the 83 
isolates are shown in Figure 3.6A and for the controls and isolate 12 in Figure 3.6B. 
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Figure 3.6 Genotyping of C. difficile clinical isolates using high-resolution 
amplicon melting-curve analysis with differences plotting of 83 isolates and 
five controls (A). R20291 was the reference genotype (base curve) for the 
difference analysis. B difference plots for three C. difficile ribotype 027 
numbered as 95, 97, and 98; (KI, M7404 and CD196) and clinical isolate 
number 12. Ribotype 027 R20291 number 96 was the reference genotype (base 
curve) for the HRM analysis (plots as a straight line at zero). 
Figure 3.6A shows that the curves differ from that of the control 027 strain (isolate 96) 
from around +15 at 82ºC to around -24 at 80.5ºC. In Figure 3.6B it can be seen that the 
difference curves for the control strains (except M7404) are all within +/- 1 including 
isolate 12. Isolate 97 (control M7404) on the other hand has greater values of difference yet 
not as great as some other curves shown in Figure 3.6A. 
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Using R20291 ribotype 027 reference strain for HRM genotyping, Rotor-Gene software can 
calculate from these difference curve values the likelihood that isolates are related. KI, 
CD196 ribotype 027 control strains and isolate number 12 have confidences of 94.33%, 
97.28% and 97.76% respectively of being the same genotype as R20291 (Table 3.1). The 
M7404 ribotype 027 Canadian strain showed a confidence of 71.36%, the lower confidence 
of R20291 is expected from the different pattern shown in Gelcompar II (Figure 3.3). 
   Table 3.1 Confidences of KI, M7404 and CD196 and isolate number 12 to R20291  
Seq. Number  Name  Genotype  Confidence %  
95  KI  R20291  94.33  
96  R20291  R20291  100.00  
97  M7404  Variation  71.36  
98  CD196  R20291  97.28  
12  Clinical isolate  R20291  97.76  
 
3.3.3 Real-time PCR with HRM analysis using DNA extracted from stool   
The real-time PCR with HRM analysis was performed on the Rotor-Gene 6000 (QIAGEN) 
in duplicates using DNA extracted from pure culture of 20 C. difficile clinical isolates and 
DNA extracted from stool samples of these 20 isolates to be cycled in the same run. Figure 
3.7 shows the amplification profile of real-time and the differences in Ct values between 
group A (isolate DNA) and group B (stool DNA). 
 
The mean Ct value for group B (Figure 3.7) was 25.7 (SD = 1.4) which was higher than the 
Ct value for group A which was 13.2 (SD = 1) (Figure 3.7). 
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Figure 3.7 Amplification profile of real-time PCR for two different groups (A) 
DNA extracted from pure culture (B) DNA extracted from stool samples. 
The raw data obtained by HRM analysis for two groups of C difficile using DNA extracted 
by two different methods are shown in Figure 3.8. Figure 3.8B shows that there is a greater 
range of fluorescence values and ending melt temperatures. This would be expected to 
affect the analysis downstream. 
 
 
 
 
 
 
 
Figure 3.8 HRM raw data showing different starting and ending points for 20 C. 
difficile clinical isolates using (A) DNA extracted from pure culture (B) DNA extracted 
from stool samples. 
After normalization, Figure 3.9B shows that there has been a change to the melt-curve 
characterization of stool DNA compared to that of isolate DNA. 
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Figure 3.9 HRM normalized graph for 20 C. difficile clinical isolates using (A) DNA 
extracted from pure culture and (B) DNA extracted from stool samples.  
HRM melt peak analysis for 20 C. difficile clinical isolates using DNA extracted from pure 
culture and the same 20 isolates using DNA extracted directly from stool samples are 
shown in Figure 3.10. 
 
 
 
 
 
 
Figure 3.10 HRM melt peak analysis for 20 C. difficile clinical isolates using (A) DNA 
extracted from pure culture and (B) DNA extracted from stool samples.  
The HRM melt peaks obtained by using DNA extracted directly from stool samples (Figure 
3.10A) have different peaks compared to the HRM melt peak obtained by using DNA 
extracted from pure culture of the same 20 C. difficile clinical isolates (Figure 3.10B). The 
differential height of peaks is almost half in Figure 3.10B compared to Figure 3.10A. This 
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Temperature  Temperature  
A  B  
A  B  
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probably indicates weak banding products so no further evaluation of stool DNA for HRM 
ribotyping was performed. 
 
3.3.4 ScreenClust data analysis 
ScreenClust HRM software was used to analyse whether clusters of isolates could be 
identified from the HRM data obtained by Rotor-Gene operating software. As previously 
stated ten clinical isolates (21, 23, 43, 45, 73, 79, 82, 83, 89 and 94) were excluded from 
analysis as they showed abnormal melt curves and high Ct value greater than 25. The HRM 
raw data for 83 C. difficile clinical isolates and five control strains are shown in Figure 
3.11.  
 
 
Figure 3.11 HRM raw data showing different starting points of 
fluorescence for 83 C. difficile clinical isolates and 5 reference 
strains.  
Figure 3.12 shows the normalisation curves of imported data from the HRM of 83 C. 
difficile clinical isolates and five control strains used in this study. It can be seen that the 
Screenclust software produces similar normalised melt curves in Figure 3.12 to that 
produced by Rotor-Gene software (Figure 3.4A). 
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Figure 3.12 Normalized HRM curves for 83 C. difficile clinical isolate 
and five reference strains obtained.  
After normalization using ScreenClust software a residual plot was generated by 
ScreenClust, the software defaults to use the data as a basis to produce principal component 
analysis by extracting a set of features for each curve. Principal component analysis selects 
the linear combination of the data vector that shows the most variation among the isolates 
as the first principal component (PC). The data is first analysed using unsupervised mode 
for clustering of the data. The software was able to associate isolates to 12 clusters and 
these clusters were each assigned a colour. These colours were used subsequently to label 
lines in the preceding Figures 3.3-3.14. The clusters of isolates are shown in Figure 3.13. 
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Figure 3.13 Twelve clusters generated from principal component data analysis of 
88 C. difficile isolates differentiated by colours created by software default 
according to genotype with 3 dimensional shapes A, B and C. 
The isolates corresponding to each cluster are shown in Table 3.2. 
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Table 3.2 Eighty-three C. difficile isolate and five control strains differentiated into 12 
clusters 
Cluster No. Colour Representative Isolates 
01 __________ 15, 90, 97*, 53, 60 
02 __________ 04, 05, 08, 25, 46, 65, 70 
03 __________ 16, 41, 69, 87 
04 __________ 12, 20, 28, 33, 37, 76, 78, 80, 95*, 96*, 98* 
05 __________ 14, 34, 40, 44, 71, 77, 84, 92 
06 __________ 02, 17, 29, 32, 36, 42, 52 
07 __________ 06, 30, 50, 54, 56, 61, 68, 91 
08 __________ 03, 11, 18, 19, 22, 26, 31, 63, 81, 86 
09 __________ 01, 07, 09, 27, 62, 74 
10 __________ 10, 13, 24, 35, 49, 51, 64, 66, 72, 88 
11 __________ 39, 48, 55, 57, 58, 59, 67, 75, 85 
12 __________ 38, 47, 93 
* Ribotype 027 reference strains. 
 
ScreenClust software grouped eight isolates into the same cluster (Table 3.2, cluster 4) with 
three ribotype 027 reference strains. As previously shown in Table 3.1, the homology of 
isolate 12 when examined by difference genotyping was 98% to the control strain R20291. 
The homology of these clustering isolates 20, 28, 33, 37, 76, 78 and 80 was found to be 
63.6%, 46.6%, 59.8%, 90.5%, 58.5%, 52.7% and 48.4% respectively. Non of these other 
isolates were found in the same group when analysed by GelCompar II and in addition only 
isolates 12 and 78 showed the same toxin profile compared to ribotype 027 control strains 
(Figure 3.3). Isolate 12 had been shown to be ribotype 027, isolate 78 as stated above only 
had 52.7% homology with the control strain R20291. M7404 ribotype 027 control strain 
was not found in the same cluster with the other three 027 reference strains and it also has a 
different ribotype pattern as shown in Figure 3.3. The analysis was repeated in supervised 
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mode using R20291 ribotype 027 strain as a control. A subset of the clusters resulting from 
this analysis and containing 027 strains is presented in Figure 3.14. 
 
 
 
 
 
 
 
Figure 3.14 Two clusters generated from principal component data analysis using 
R20291 as a control strain in supervised mode and the clinical isolate 12 and the four 
ribotype 027 strains. 
In Figure 3.14, isolate 12 shows close association with the control strains. 
 
3.3.5 Measurement of discriminatory power  
Using Simpson's index of diversity to measure the discriminatory power of PCR-ribotyping 
and HRM using ScreenClust software for data analysis with the same total number of 
isolates (88 isolates) showed PCR-ribotyping to have an index of 0.902 and HRM had an 
index of 0.928. 
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3.4 Discussion 
Typing of C. difficile using the variation in ISR was first described by Gurtler (1993). The 
current study uses real-time PCR to produce the ISR amplicons and is the first time that 
HRM with ScreenClust software has been used to analyse ISR's for ribotyping. It has been 
reported that bands generated by PCR-ribotyping in C. difficile may only differ in size by 
less than 10 nucleotides (Gurtler, 1993). Thus one limitation of PCR-ribotyping is that 
agarose gel separation of PCR products may lack resolution. The bands generated by early 
PCR-ribotyping methods exhibited bands with high and close molecular masses, thus some 
patterns were difficult to read on the agarose gel electrophoresis (Gurtler, 1993, Kostman et 
al., 1992). A modification of the method was developed in order to reduce the size of PCR 
generated fragments by choosing new primers closer to the ISR (O'Neill et al., 1996). In 
this study we used PCR-ribotyping primers that were located closer to the ISR and give 
shorter PCR products (Bidet et al., 1999). This method gave clear separate bands ranging 
from 260 to 2176 bp when separated on agarose gel electrophoresis. The modified PCR-
ribotyping method of Bidet et al. (1999) showed high discriminatory power calculated as 
0.902 by Simpson's index. PCR-ribotyping has been considered to be a more discriminatory 
approach than arbitrary-primer PCR (AP-PCR) for typing C. difficile (Collier et al., 1996) 
but less than PFGE in discriminatory power (Brazier, 1998). 
 
GelCompar II was used to analyse 88 C. difficile isolates and four ribotype 027 strains 
resulting in the identification of a clinical isolate (isolate number 12) with an identical 
ribotyping pattern to three control strains and HRM genotyping confidence of 98%. This 
isolate has a toxin gene profile identical to those of the control 027 group. The similarity of 
this isolate to control isolates was confirmed by ScreenClust where this isolate was found to 
cluster with the 027 group. Warny et al. (2005) showed that M7404 (Canadian ribotype 027 
strain) has a slightly different PFGE pattern, but did not mention if the ribotype pattern 
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varied. In this study we found that M7404 had a slightly different ribotyping pattern but 
still grouped with 027 strains using GelCompar II. Similarity using HRM ribotyping, 
M7404 did not cluster with the control 027 strains. It would be interesting to investigate 
further isolates from Canada to see if they consistently are identified within a unique 
cluster. 
 
In the study performed by Stabler et al. (2006) comparative phylogenomics was applied to 
model the phylogeny of C. difficile including 75 diverse isolates. Four identified  distinct 
statistically supported clusters were identified and among these only 19.7% of 
characteristics were shared by all strains confirming that this enteric species readily 
undergoes genetic exchanges. Further to this,  Stabler et al. (2010) stated that “C. difficile 
has a highly fluid genome with multiple mechanisms to modify its genetic content and is 
continuing to evolve in our hospitals influenced by environmental changes and human 
activity”.  
 
Comparing the historical CD196 strain with the modern hypervirulent strain R20291 
showed that this modern strain has five additional genetic regions compared to its historic 
counterpart. Furthermore both 027 strains have an additional 234 genes compared to C. 
difficile 630 strain, which may account for the marked increase in disease capability 
(Stabler et al., 2009). However, in bacteria there are other mechanisms of genetic variation, 
and perhaps counter intuitively gene re-arrangements and gene loss can be equally 
important in the evolution of virulence (Pallen and Wren 2007). 
 
Isolate number 90 also grouped with the 027 controls when analysed by GelCompar II, 
however it has a different toxin gene profile. This isolate did not cluster with 027 controls 
when analysed by ScreenClust software. This reinforces the importance of firstly 
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determining what toxin genes are present. Isolates with suspicious toxin gene profiles may 
then be further examined by ribotyping methods. Figure 3.3 lists the results of CTA testing 
of isolates. If we look at particular groups, for instance the first two isolates in group four, 
we can see that although there is greater than 90% homology for these two isolates (75 and 
85), they gave different CTA results. CTA testing has been found to be poorly sensitive at 
76.7% (Peterson et al., 2007) and 67.2% (Stamper et al., 2009a) and this would seem to be 
confirmed by the results of the current study. 
 
HRM analysis allows for both visual- and auto-calling of genotypes. Results can be viewed 
as either a normalized melt plot or a difference plot. Normalized curves of the 88 C. 
difficile including four ribotype 027 strains shown in Figure 3.4A demonstrated variation of 
curves between isolates. In Figure 3.4B it can be noted that that isolate number 12 has a 
melt curve similar to that of ribotype 027 strains (CD196, KI AND R20291), however the 
Canadian strain M7404 has a slightly different melt curve as shown in Figure 3.4B. This 
finding was confirmed by difference plots when using the UK strain (R20291) as control 
for genotyping as shown in Figure 3.5B and Table 3.1. The difference plots provide an 
alternative view of the differences between melt curve transitions. It should be noted that it 
would not be expected to get the same grouping of isolates using HRM analysis of PCR-
ribotyping and gel separation of PCR-ribotyping products. The HRM curve is produced as a 
combination of all PCR fragmented generated rather than separate analysis of each 
fragment. It would be interesting to see sequencing of the M7404 strain in order to compare 
the inter spacer region of this strain to other 027 strains. From the HRM data it would seem 
there are a number of differences (Figure 3.5B). 
 
Twelve clusters were generated from principle component analysis of HRM data when 
analysed in unsupervised mode. Isolate number 12 was in the same cluster as the three 
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ribotype 027 reference strains. Even when supervised mode is used in ScreenClust M7404 
does not cluster with the other 027 strains. This raises the possibility that ScreenClust might 
be useful to investigate isolates from Canada and then M7404 would be selected as control 
in supervised mode. It was found that an isolate with a similar toxin profile (isolate 78) also 
clustered with the control 027 strains. It would be important to consider the tcdC deletion 
carry as important additional information. Isolate 78 was found to have a deletion in tcdC 
(Chapter 2, Figure 2.5), however it was not the signature deletion of other 027 strains. 
 
Once DNA has been extracted, PCR-ribotyping requires around eight hours to achieve a 
result, while HRM using ScreenClust for data analysis can be performed in less than two 
hours. Although it would be desirable to be able to perform HRM ribotyping directly from 
stool, this was not expected to be feasible. As the result showed, the Ct values were lower 
from stool and melt peaks less defined. Additionally if HRM ribotyping is performed 
directly from stool, it could be expected that the ISR of other closely related Clostridium 
spp. may also be amplified thus further confusing the melt peaks obtained. 
 
Using Simpson's index of diversity to measure and compare the discriminatory power 
between PCR-ribotyping and HRM analysis developed in this study showed PCR-
ribotyping to have an index of 0.902 and HRM of 0.928. This index indicates that if two 
strains were sampled randomly from the population by PCR ribotyping, then on 90% of 
occasions they would fall into different types. HRM analysed through ScreenClust has a 
similar discriminatory value (92%) to that of PCR ribotyping. Further work would be 
required in a clinical setting to see if the HRM ribotype clusters are clinically relevant.  
 
In conclusion, ScreenClust software was capable of detecting, clustering and calling 
genotypes from various HRM data sets in a short time. The difference in the Ct values and 
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curve characteristic of the real-time PCR obtained from isolate DNA would suggest that 
HRM PCR-ribotyping cannot be performed directly from stool. However since PCR toxin 
typing is suggested to be performed first and can be performed the same day as stool 
receipt, it is feasible to perform culture on stool from suspicious PCR toxin types and then 
batch test these isolates in HRM ribotyping. 
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CHAPTER 4 
General discussion and future directions 
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4. General discussion and future directions 
The emergence and spread of the epidemic strain PCR ribotype 027 has caused many 
outbreaks around the world (McDonald et al., 2005, Kuijper et al., 2006, Kuijper et al., 
2008). Outbreaks are continuing to occur in Canada (CBC, 2011), and Australia (Wang et 
al., 2011). Muto et al. (2007) have published methods used to control outbreaks in the USA 
and they stated that early identification of cases was important for effective control. The 
limitations of traditional testing for CDAD are due to the lack of sensitivity when detecting 
toxin in stool, the slowness of testing when performing cytotoxic culture and the lack of 
specificity when performing C. difficile isolation. Laboratory testing for C. difficile is being 
facilitated by the next generation of tests based on PCR methodologies.  
 
Currently in the USA many of the commercially available Federal Drug Administration 
(FDA) approved PCR tests are based on detecting the TcdB gene. An example of the 
danger of using a PCR test based on one gene was seen when Neisseria gonorrhoea mutant 
isolates were no longer detected by commercial assays (Farrell, 1999, Tabrizi et al., 2004). 
It is not only commercial assays that are prone to this problem as was described recently 
when an in-house assay for N. gonorrhoea also failed to detect an isolate due to sequence 
variation of the target gene (Whiley et al., 2004). In the current study, significant sequence 
variation was found when the primers published by Wroblewski et al. (2009) were 
compared to recently published sequences of C. difficile. As the assay used in the current 
study was developed in-house, the primers were able to be quickly redesigned and applied.  
 
To overcome the problems of testing for one gene, the current study chose a multiplex 
PCR. The current study showed that the multiplex real time PCR for detection of C. 
difficile toxin genes tcdA and tcdB as well as binary toxin cdtA and cdtB using DNA 
extracted by an automated system gave reliable results when compared to CTA and 
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conventional PCR. Including PCR primers for binary toxin genes in C. difficile multiplex 
testing would seem to be important especially as tcdA_ tcdB_ binary toxin positive isolates 
have been reported and that binary toxin in a suspected virulence factor in C. difficile 
(Barbut et al., 2005).  
 
TcdA gene negative, TcdB gene positive isolates have been reported (Lyerly et al., 1992). 
On further examination of these isolates it was found that parts of tcdA were truncated. The 
Wroblewski et al. PCR primers for tcdA used in the current study detect tcdA regardless of 
whether there is a truncation present. It was interesting to review the results of PCR 
conventional testing where some bands were weak. Thus the rationale for testing using both 
tcdA and tcdB primers was decided as a way of controlling for both. It could be seen in the 
current study that signal strength also varied in real-time PCR. Thus testing for both tcdA 
and tcdB could be seen as creating a control for each gene in case one gene produced weak 
signals. 
 
Real-time PCR is able to produce results in around a quarter of the time for conventional 
PCR. A meta-analysis has been performed to determine the diagnostic accuracy of real-time 
PCR (Deshpande et al., 2011). This meta-analysis reported that real-time PCR has a high 
sensitivity and specificity when compared with cell culture cytotoxicity neutralisation assay 
(CCCNA) or anaerobic toxigenic culture (TC) (Deshpande et al., 2011). Interestingly, none 
of the in-house real time PCR reported in the meta-analysis are approved by the FDA. This 
is probably because extensive testing is required before FDA approval is granted and this is 
beyond the financial ability of most laboratories. A study reported by Stamper et al. (2009a) 
reported that upon initial testing, the BD GeneOhm Cdiff assay (FDA) compared 
favourably to the Wampole C. difficile Toxin B test with a sensitivity and specificity of 
90.9% and 95.2%, respectively. When both assays were compared to anaerobic toxigenic 
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culture, the sensitivity of the BD GeneOhm Cdiff assay dropped to 83.6%, but its 
specificity improved to 98.2% (Stamper et al., 2009a). More recently a study performed by 
Knetsch et al. (2011) compared the diagnostic values of three in-house real-time PCRs and 
a commercially available BD GeneOhm Cdiff assay, using the cytotoxigenic culture as a 
gold standard. They showed that the sensitivity of the in-house real-time PCRs was better 
than the BD GeneOhm test, but in contrast the specificity of the commercial test was 
superior to the in-house test (Knetsch et al., 2011). The sensitivity and specificity of the in-
house PCR assay of the current study should be compared to commercial assays as this will 
determine if the in-house assay produces superior results. It is important that laboratories be 
encouraged to benchmark their assays so that the best assay for any particular patient 
population be used and so that commercial manufacturers are encourage to improve their 
assays if they are found to underperform in-house assays. 
 
Future studies should be performed to work out the true sensitivity and specificity of the 
real-time testing platform described in this study. To do this would require that the best 
current gold-standard be used. Unfortunately the current best gold-standard is cytotoxigenic 
culture but this takes at least four days. Stool samples would be tested prospectively rather 
than the retrospective collection of the current study. Future studies should be performed in 
conjunction with physicians so that good clinical data can be collected. Clinical information 
will help to identify those patients with severe CDI and ensure that laboratory testing 
correlates with clinical finding. 
  
Ribotype 027 strains have been associated with severe CDI. It is important to quickly 
identify these strains before they cause hospital outbreaks. The publication of de Boer et al. 
(2010) reported the first Taqman based real-time PCR capable of detecting the tcdC Δ117 
mutation in ribotype 027 strains without the need of melting curve analysis. We have 
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shown the utility of this method in our study and have additionally added the scatter 
plotting analysis. Knetsch et al. (2011) reported a sensitivity and specificity of 98.0% and 
90.7% respectively for a real-time PCR targeting the tcdC frameshift mutation at position 
117 (Δ117 PCR) in stool samples when compared with PCR-ribotyped CYTGC-positive 
samples. Future work by our group would aim to determine the sensitivity and specificity 
of the de Boer et al. method in comparison to the Knetsch et al. method. The real-time PCR 
assay targeting Δ117 using DNA extracted by an automated system in our study would 
seem to give reliable results when using scatter plotting software for clustering 027 strains 
in this study. 
 
In the second part of the current study, ScreenClust software was demonstrated to be 
capable of detecting, clustering and calling genotypes from various HRM data sets in a 
short time. The difference in the Ct values and curve characteristic of the real-time PCR 
obtained from isolate DNA and stool DNA would suggest that HRM PCR-ribotyping 
cannot be performed directly from stool. However since PCR toxin typing is suggested to 
be performed first and can be performed the same day as stool receipt, it is feasible to 
perform culture on stool from suspicious PCR toxin types and then batch test these isolates 
in HRM ribotyping.  
 
The current study also provides evidence that there are other isolates present in the study 
population with a toxin profile similar to that of ribotype 027/NAP1, despite being of 
different ribotype. These other isolates could be important sources of further outbreaks and 
should be followed in the future to watch for changes in clusters of isolates that may be 
caused by strains with binary toxin genes. He et al. (2010) stated that “Clostridium difficile 
has rapidly emerged as the leading cause of antibiotic-associated diarrheal disease, with the 
transcontinental spread of various PCR ribotypes, including 001, 017, 027 and 078. 
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However, the genetic basis for the emergence of C. difficile as a human pathogen is 
unclear”. 
 
In Europe other strains have emerged to become important nosocomial pathogens. In a 
study performed in 2002 more than 66 different PCR ribotypes were reported from 354 
toxinogenic C. difficile isolates. “The distribution was varied markedly among hospitals and 
countries. Of all toxinogenic isolates, ribotype 001 was the most common (13%), followed 
by ribotype 014 (9%); ribotypes 002, 012, 017, 020, and 027 were each found in 6% of 
toxinogenic isolates, whereas ribotype 078 was found in 3% of toxinogenic isolates” 
(Freeman et al., 2010). Our study was unable to identify these other possible outbreak 
strains so future studies would obtain control isolates from these other epidemiologically 
important ribotypes and would further study possible de-novo identified clusters. 
 
In conclusion, this study has adapted a real-time PCR for C. difficile toxin gene testing to 
direct testing of stool via automated DNA extraction. This PCR has produced reliable 
results and should be further investigated in a prospective study. Secondly we have found 
that scatter plotting software identified the mutation that is signature of the hypervirulent 
strain and may provide same day information crucial for rapid identification and infection 
control. Finally HRM analysis of PCR-ribotyping produces clusters of isolates that 
identified the epidemic strain in a patient. This novel typing technique shows the potential 
to provide same day typing for bacterial isolates. This novel approach to typing should also 
be further investigated in a prospective study to show whether it aids in the control of C. 
difficile infection. 
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Appendix A:  Gel images for Conventional PCR using DNA extracted from pure 
culture. 
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Figure A.1 Amplification of 16s rDNA (1062 bp), tcdA (629 bp), tcdB (410 bp), 
cdtA (221 bp) and cdtB (262 bp) by multiplex conventional PCR in 13 C. difficile 
isolates. Lane 1 and 27 are DNA marker VI (154-2176 bp); lanes 2-25 representing 
C. difficile isolates number 25-48; lane 26 is NTC. 
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Figure A.2 Amplification of tcdA (629 bp) and tcdB (410 bp) by 2-plex 
conventional PCR in 24 C. difficile isolates. Lane 1 is DNA marker VI (154-2176 
bp); lanes 2-25 representing C. difficile isolates number 25-48; lane 26 is a NTC. 
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Figure A.3 Amplification of tcdA (629 bp) and tcdB (410 bp) by 2-plex 
conventional PCR in 23 C. difficile isolates. Lane 1 is DNA marker VI (154-2176 
bp); lanes 2-24 representing C. difficile isolates number 49-71; lane 25 is a NTC. 
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Figure A.4 Amplification of tcdA (629 bp) and tcdB (410 bp) by 2-plex conventional 
PCR in 17 C. difficile isolates. Lane 1 is DNA marker VI (154-2176 bp); lanes 2-18 
representing C. difficile isolates number 72-88; lane 19 is NTC. 
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Figure A.5 Amplification of tcdA (629 bp) and tcdB (410 bp) by 2-plex conventional 
PCR. Lane 1 is DNA marker VI (154-2176 bp); lanes 02-07 representing C. difficile 
isolates number 89-94; lanes 08-11 C. difficile ribotype 027 controls 95, 96, 97 and 
98; (KI, R20291, M7404 and CD196) respectively; lane 19 is a NTC. 
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Figure A.6 Amplification of cdtA (221 bp) and cdtB (262 bp) by 2-plex 
conventional PCR. Lanes 1 is DNA marker V (8-587 bp); lanes 2-25 
representing C. difficile isolates number 01-24; lane 26 is a NTC. 
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Figure A.7 Amplification of cdtA (221 bp) and cdtB (262 bp) by 2-plex 
conventional PCR. Lanes 1 is DNA marker VI (154-2176 bp); lanes 2-24 
representing C. difficile isolates number 49-71; lane 25 is a NTC. 
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Figure A.8 Amplification of cdtA (221 bp) and cdtB (262 bp) by 2-plex 
conventional PCR. Lanes 1 is DNA marker VI (154-2176 bp); lanes 2-18 
representing C. difficile isolates number 72-88; lane 19 is a NTC. 
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Figure A.9 Amplification of cdtA (221 bp) and cdtB (262 bp) by 2-plex conventional 
PCR. Lane 1 DNA marker VI (154-2176 bp); lanes 02-07 representing C. difficile 
isolates number 89-94; lanes 08-11 C. difficile ribotype 027 controls 95, 96, 97 and 
98; (KI, R20291, M7404 and CD196) respectively; lane 12 is a NTC. 
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Figure A.10 Amplification of tcdC (475 bp) by conventional PCR. Lanes 1 is DNA 
marker VI (154-2176 bp); lanes 2-25 representing C. difficile isolates number 1-24; 
lane 26 is a NTC. 
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Figure A.11 Amplification of tcdC (475 bp) by conventional PCR. Lanes 1 is DNA 
marker VI (154-2176 bp); lanes 2-24 representing C. difficile isolates number 49-71; 
lane 25 is a NTC. 
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Figure A.12 Amplification of tcdC (475 bp) by conventional PCR. Lanes 1 and 20 is 
DNA marker V (8-587 bp); lanes 2-18 representing C. difficile isolates number 72-88; 
lane 19 is a NTC. 
 
 
 
                  01          02         03         04         05          06          07         08          09        10         11          12   
 
Figure A.13 Amplification of tcdC (475 bp) by conventional PCR. Lane 1 DNA 
marker V (8-587 bp); lanes 02-07 representing C. difficile isolates number 89-94; 
lanes 08-11 C. difficile ribotype 027 controls 95, 96, 97 and 98; (KI, R20291, M7404 
and CD196) respectively; lane 12 is a NTC. 
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Appendix B: Gel images for cconventional PCR using DNA extracted from stool 
samples 
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Figure B.1 Amplification of tcdA resulting in a 629 bp product by conventional PCR 
using stool DNA. Lanes 1 and 26 are DNA molecular weight marker VI (154-2176 
bp); Lanes 02-24 representing stool samples number (52, 53, 54, 55, 56, 57, 59, 63, 
64, 66, 69, 71, 74, 75, 76, 77, 78, 79, 81, 82, 83, 84 and 86); lane 25 negative control. 
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Figure B.2 Amplification of tcdA resulting in a 629 bp product by conventional PCR 
using stool DNA. Lanes 1 is DNA molecular weight marker VI (154-2176 bp); Lanes 
02-25 representing stool samples number (3, 6, 15, 16, 21, 24, 28, 30, 33, 34, 45, 47, 
48, 61, 62, 65, 72, 73, 80, 85, 87, 88, 90 and 91); lane 26 is a negative control. 
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Figure B.3 PCR products from amplification of tcdB (410 bp) by conventional PCR 
using stool DNA. Lanes 1 and 26 are DNA molecular weight marker VI (154-2176 
bp); Lanes 02-24 representing stool samples number (52, 53, 54, 55, 56, 57, 59, 63, 
64, 66, 69, 71, 74, 75, 76, 77, 78, 79, 81, 82, 83, 84 and 86); lane 25 negative 
control. 
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Figure B.4 PCR products from amplification of tcdB (410 bp) by conventional PCR 
using stool DNA. Lanes 1 is DNA molecular weight marker VI (154-2176 bp); Lanes 
02-25 representing stool samples number (3, 6, 15, 16, 21, 24, 28, 30, 33, 34, 45, 47, 
48, 61, 62, 65, 72, 73, 80, 85, 87, 88, 90 and 91); lane 26 is a negative control. 
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Figure B.5 Amplification of cdtA 221 bp products and cdtB 262 bp products by 
conventional PCR using stool DNA in 23 stool samples. Lanes 1 and 26 are DNA 
molecular weight marker VI (154-2176 bp); Lanes 02-24 representing stool samples 
number (52, 53, 54, 55, 56, 57, 59, 63, 64, 66, 69, 71, 74, 75, 76, 77, 78, 79, 81, 82, 
83, 84 and 86); lane 25 negative control. 
 
 
                 01   02   03   04   05   06   07   08   09  10   11   12   13   14   15   16   17  18   19   20   21   22   23   24   25   26 
 
Figure B.6 Amplification of cdtA 221 bp products and cdtB 262 bp products by 
conventional PCR using stool DNA of 24 stool samples. Lanes 1 is DNA molecular 
weight marker VI (154-2176 bp); Lanes 02-25 representing stool samples number 
(3, 6, 15, 16, 21, 24, 28, 30, 33, 34, 45, 47, 48, 61, 62, 65, 72, 73, 80, 85, 87, 88, 90 
and 91); lane 26 is a negative control. 
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Appendix C: Multiplex real-time PCR using DNA extracted from stool samples by an 
automated system. 
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Figure C.1 Amplification of tcdA for samples 46-70 by multiplex real-time PCR. Red 
curves were tcdA positive samples while the green lines were tcdA negative samples. 
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Figure C.2 Amplification of tcdB for samples 46-70 by multiplex real-time PCR. Red 
curves refer to tcdB positive samples while the green lines were tcdB negative 
samples. 
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Figure C.3 Amplification of cdtA for samples 46-70 by multiplex real-time PCR. Red 
and green lines were cdtA negative samples. 
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Figure C.4 Amplification of cdtB for samples 46-70 by multiplex real-time PCR. Red 
and green lines were cdtB negative samples. 
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Figure C.5 Amplification of internal control for samples 1-45 by multiplex real-time 
PCR. Red and green curves were IC positive samples while the green line was NTC. 
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Figure C.6 Amplification of internal control for samples 46-70 by multiplex real-
time PCR. Red and green curves were IC positive samples while the green line was 
NTC. 
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